image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
72afa18de3fd3ef5c5918be6d1af39d8cdcb4ac09f2b9260438a3122266c0d9c.png | complex | <table><tr><td>miRNA Migr. / Inv. / Met.</td><td>Targets</td><td>Cells / Tissue</td><td>Expression</td><td>Function</td><td>Reference</td></tr><tr><td>miR-17 family (20a, 20b)</td><td>TGFßR2</td><td>A549/CDDP</td><td>down</td><td>TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases</td><td>[8... | <table><tr><td>miRNA Migr. / Inv. / Met.</td><td>Targets</td><td>Cells / Tissue</td></tr><tr><td>miR-17 family (20a, 20b)</td><td>TGFßR2</td><td>A549/CDDP</td></tr><tr><td>miR-21</td><td>PTEN</td><td>Serum, NSCLC cells</td></tr><tr><td>mir-26b</td><td>PTEN</td><td>NSCLC tissue, NSCLC cells</td></tr><tr><td>miR-27a</td>... | <table><tr><td>Expression</td><td>Function</td><td>Reference</td></tr><tr><td>down</td><td>TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases</td><td>[81]</td></tr><tr><td>up</td><td>Promotes migration, invasion and metastasis</td><td>[9]</td></tr><tr><td>down</td><td>Regulates NSCLC migration and CD... |
86819affa162f5883bd2baf27ed966441ecd2aac6efd775eb6c7ed5c01e6688b.png | simple | <table><tr><td></td><td>AC-</td><td>AC+</td></tr><tr><td>2.5 Gy/fraction</td><td>94 (A1)</td><td>83 (A3)</td></tr><tr><td>2.0 Gy/fraction</td><td>142 (A2)</td><td>114 (A4)</td></tr></table> | <table><tr><td></td></tr><tr><td>2.5 Gy/fraction</td></tr><tr><td>2.0 Gy/fraction</td></tr></table> | <table><tr><td>AC-</td><td>AC+</td></tr><tr><td>94 (A1)</td><td>83 (A3)</td></tr><tr><td>142 (A2)</td><td>114 (A4)</td></tr></table> |
069b2ffed479cef0278b60a392eb3238f35b0651e83b6f772225bd5be452de33.png | complex | <table><tr><td rowspan="2">Gene ID</td><td colspan="3">Log<sub>2</sub> (RPKM<sub>OXR</sub>/RPKM<sub>WT</sub>)</td><td rowspan="2">Description</td></tr><tr><td>0 h</td><td>6 h</td><td>24 h</td></tr><tr><td colspan="5">Catalase (CAT)</td></tr><tr><td>Os06t0727200-01</td><td>0.79</td><td>1.36 **</td><td>0.79</td><td>catal... | <table><tr><td rowspan="2">Gene ID</td><td colspan="3">Log2 (RPKMOXR/RPKMWT)</td><td rowspan="2">Description</td></tr><tr><td>0 h</td><td>6 h</td><td>24 h</td></tr><tr><td colspan="5">Catalase (CAT)</td></tr><tr><td>Os06t0727200-01</td><td>0.79</td><td>1.36 **</td><td>0.79</td><td>catalase isozyme B (EC 1.11.1.6)</td><... | <table><tr><td rowspan="2">Gene ID</td><td colspan="3">Log2 (RPKMOXR/RPKMWT)</td><td rowspan="2">Description</td></tr><tr><td>0 h</td><td>6 h</td><td>24 h</td></tr><tr><td>Os01t0263300-01</td><td>0.44</td><td>1.42 **</td><td>−0.6</td><td>similar to peroxidase 72 precursor (EC 1.11.1.7)</td></tr><tr><td>Os01t0962700-01<... |
33c414e689ec1b56672aecf6d272d53ca0e00f4ec0c1f0cfa129dddd4de9ec69.png | complex | <table><tr><td>50 years +</td><td colspan="2">Female</td><td colspan="2">Male</td><td colspan="2">Total</td></tr><tr><td></td><td>N</td><td>%</td><td>n</td><td>%</td><td>N</td><td>%</td></tr><tr><td>Circulatory system diseases</td><td>29</td><td>27.6</td><td>19</td><td>18.6</td><td>48</td><td>23.2</td></tr><tr><td>Tube... | <table><tr><td>50 years +</td><td>Female</td></tr><tr><td></td><td>N</td></tr><tr><td>Circulatory system diseases</td><td>29</td></tr><tr><td>Tuberculosis</td><td>7</td></tr><tr><td>Malaria</td><td>8</td></tr><tr><td>Intestinal infectious diseases (diarrhea)</td><td>3</td></tr><tr><td>Malignant neoplasms</td><td>5</td>... | <table><tr><td>Female</td><td colspan="2">Male</td><td colspan="2">Total</td></tr><tr><td>%</td><td>n</td><td>%</td><td>N</td><td>%</td></tr><tr><td>27.6</td><td>19</td><td>18.6</td><td>48</td><td>23.2</td></tr><tr><td>6.7</td><td>10</td><td>9.8</td><td>17</td><td>8.2</td></tr><tr><td>7.6</td><td>8</td><td>7.8</td><td>... |
8d2f0fba4ded7277dc979d18dd963bdfae5e5a130385538edf293b668d77389b.png | simple | <table><tr><td>Device</td><td>Structure</td><td>Thickness (nm)</td><td><i>a</i> (nm)</td><td><i>n</i></td><td><i>λ</i> (nm)</td><td><i>s</i> (μm)</td><td><i>η</i></td></tr><tr><td>A1</td><td>YIG/Ti/Co</td><td>20/1/25</td><td>200</td><td>2, 4</td><td>100</td><td>30</td><td>95%</td></tr><tr><td>A2</td><td>... | <table><tr><td>Device</td><td>Structure</td></tr><tr><td>A1</td><td>YIG/Ti/Co</td></tr><tr><td>A2</td><td>YIG/Ti/Co</td></tr><tr><td>A3</td><td>YIG/Ti/Co</td></tr><tr><td>A4</td><td>YIG/Al2O3/Co</td></tr><tr><td>B1</td><td>YIG/Ti/Ni</td></tr><tr><td>C1</td><td>YIG/Ti/CoFe</td></tr><tr><td>C2</td><td>YIG/Al2O3/CoFe</td>... | <table><tr><td>Thickness (nm)</td><td>a (nm)</td><td>n</td><td>λ (nm)</td><td>s (μm)</td><td>η</td></tr><tr><td>20/1/25</td><td>200</td><td>2, 4</td><td>100</td><td>30</td><td>95%</td></tr><tr><td>20/1/25</td><td>180</td><td>2, 4, 6</td><td>60</td><td>30</td><td>106%</td></tr><tr><td>20/1/50</td><td>180</td><td>4</td><... |
a7044b7715752653954a10520b1d9dc5677a00fce4369578a9ba5b6e97c28056.png | complex | <table><tr><td>Sample</td><td colspan="2">Superoxide Anion Generation (Inh %)</td><td colspan="2">Elastase Release (Inh %)</td></tr><tr><td>A-EtOH</td><td>90.1 ± 5.3</td><td>**</td><td>85.3 ± 0.8</td><td>**</td></tr><tr><td>A-BuOH</td><td>93.9 ± 8.3</td><td>**</td><td>77.6 ± 2.4</td><td>**</td></tr>... | <table><tr><td>Sample</td></tr><tr><td>A-EtOH</td></tr><tr><td>A-BuOH</td></tr><tr><td>A-Water</td></tr><tr><td>A-EtOAc</td></tr><tr><td>A-Hexane</td></tr><tr><td>A-MeOH</td></tr><tr><td>AM1</td></tr><tr><td>AM2</td></tr><tr><td>AM3</td></tr><tr><td>AM4</td></tr><tr><td>AM5</td></tr><tr><td>AM6</td></tr></table> | <table><tr><td colspan="2">Superoxide Anion Generation (Inh %)</td><td colspan="2">Elastase Release (Inh %)</td></tr><tr><td>90.1 ± 5.3</td><td>**</td><td>85.3 ± 0.8</td><td>**</td></tr><tr><td>93.9 ± 8.3</td><td>**</td><td>77.6 ± 2.4</td><td>**</td></tr><tr><td>11.4 ± 1.6</td><td>*</td><td>2.7 ± 4.1</td><td>–</td></tr... |
b5afabe4f42bbad4cf5ce15df13037eeff8796ddf001de024bb6ee2a05a6d004.png | simple | <table><tr><td></td><td>E50</td><td>E60</td><td>E70</td></tr><tr><td>Total clean reads</td><td>57,050,205</td><td>60,029,490</td><td>61,295,544</td></tr><tr><td>Total clean nucleotides</td><td>11,410,041,000</td><td>12,005,898,000</td><td>12,259,308,800</td></tr><tr><td>Total trinity transcripts</td><td>61,057</td><td>... | <table><tr><td></td></tr><tr><td>Total clean reads</td></tr><tr><td>Total clean nucleotides</td></tr><tr><td>Total trinity transcripts</td></tr><tr><td>Total trinity components</td></tr><tr><td>Contig N50</td></tr><tr><td>Median contig length</td></tr><tr><td>Average contig</td></tr><tr><td>Total assembled bases</td></... | <table><tr><td>E50</td><td>E60</td><td>E70</td></tr><tr><td>57,050,205</td><td>60,029,490</td><td>61,295,544</td></tr><tr><td>11,410,041,000</td><td>12,005,898,000</td><td>12,259,308,800</td></tr><tr><td>61,057</td><td>342,255</td><td>192,448</td></tr><tr><td>49,282</td><td>279,928</td><td>158,626</td></tr><tr><td>1379... |
2c2395d9674077ece93f47e1d15bc3bbf433a90396972c7b4c94e4bf60fb06a3.png | simple | <table><tr><td>OD values</td><td>Biofilm formation</td></tr><tr><td>≤ODc</td><td>Non</td></tr><tr><td>2 × ODc ≤ OD > ODc</td><td>Weak</td></tr><tr><td>4 × ODc ≤ OD > 2 × ODc</td><td>Moderate</td></tr><tr><td>>4 × ODc</td><td>High</td></tr></table> | <table><tr><td>OD values</td></tr><tr><td>≤ODc</td></tr><tr><td>2 × ODc ≤ OD > ODc</td></tr><tr><td>4 × ODc ≤ OD > 2 × ODc</td></tr><tr><td>>4 × ODc</td></tr></table> | <table><tr><td>Biofilm formation</td></tr><tr><td>Non</td></tr><tr><td>Weak</td></tr><tr><td>Moderate</td></tr><tr><td>High</td></tr></table> |
64e25abec7ade13432c1e06de9221d66dd08c2f4cf3dea67e580cc14efde4a77.png | complex | <table><tr><td>Scale</td><td>Subscale</td><td> M</td><td> SD</td><td>Extreme negative responders (%)<sup>a</sup></td></tr><tr><td rowspan="4">Marcus</td><td>Prognosis for recovery (recovery)</td><td>3.01</td><td>1.37</td><td>—</td></tr><tr><td>Alcoholism and character defect (character defect)</td><td>2.59</td><t... | <table><tr><td>Scale</td><td>Subscale</td><td>M</td><td>SD</td><td>Extreme negative responders (%)a</td></tr><tr><td rowspan="4">Marcus</td><td>Prognosis for recovery (recovery)</td><td>3.01</td><td>1.37</td><td>—</td></tr><tr><td>Alcoholism and character defect (character defect)</td><td>2.59</td><td>1.22</td><td>—</t... | <table><tr><td>Scale</td><td>Subscale</td><td>M</td><td>SD</td><td>Extreme negative responders (%)a</td></tr><tr><td>SAAPPQ</td><td>Pessimism is the most attitude to take toward drinkers (pessimism)</td><td>2.85</td><td>1.40</td><td>2.0</td></tr></table> |
25ae47e661d45b275e7437513f9f9c1a91f1c52f5708b7c8b7d05d15e702c4b7.png | complex | <table><tr><td></td><td colspan="4">Patients</td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Management</td><td></td><td></td><td></td><td></td></tr><tr><td>Operation</td><td>No</td><td>Resection and IVC PTFE Patch</td><td>Resection and primary repair</td><td>Resection and IVC Vein Patch</td>... | <table><tr><td></td><td colspan="3">Patients</td></tr><tr><td></td><td>1</td><td>2</td><td>3</td></tr><tr><td>Management</td><td></td><td></td><td></td></tr><tr><td>Operation</td><td>No</td><td>Resection and IVC PTFE Patch</td><td>Resection and primary repair</td></tr><tr><td>Chemotherapy</td><td>Yes</td><td>No</td><td... | <table><tr><td>Patients</td></tr><tr><td>4</td></tr><tr><td></td></tr><tr><td>Resection and IVC Vein Patch</td></tr><tr><td>No</td></tr><tr><td>Radiotherapy</td></tr><tr><td>High</td></tr><tr><td></td></tr><tr><td>No</td></tr><tr><td>No</td></tr><tr><td>No</td></tr><tr><td></td></tr><tr><td>No</td></tr><tr><td>Alive</t... |
fc3f005704356b5711a1909e38424d8059caa9b22d067007f1a692ddea8edba1.png | complex | <table><tr><td rowspan="3">Baseline/outcome measure</td><td rowspan="3">Questionnaire</td><td colspan="4">Survey administration times</td></tr><tr><td>Baseline</td><td colspan="2">Time 1</td><td>Time 2</td></tr><tr><td>(after referral for abnormal screen)</td><td>(within 3 months of<i>negative</i>diagnosis)</td><td>(wi... | <table><tr><td rowspan="3">Baseline/outcome measure</td><td rowspan="3">Questionnaire</td><td colspan="4">Survey administration times</td></tr><tr><td>Baseline</td><td colspan="2">Time 1</td><td>Time 2</td></tr><tr><td>(after referral for abnormal screen)</td><td>(within 3 months ofnegativediagnosis)</td><td>(within 3 ... | <table><tr><td rowspan="3">Baseline/outcome measure</td><td rowspan="3">Questionnaire</td><td colspan="4">Survey administration times</td></tr><tr><td>Baseline</td><td colspan="2">Time 1</td><td>Time 2</td></tr><tr><td>(after referral for abnormal screen)</td><td>(within 3 months ofnegativediagnosis)</td><td>(within 3 ... |
dd14cd298baa5a48fe22ee76f53f48ddf9960a4401940560fcbf76dcdcf4f8f7.png | complex | <table><tr><td></td><td colspan="4">Clusters</td></tr><tr><td></td><td>The comprehensive</td><td>The theoretician</td><td>The minimalist</td><td>The structural</td></tr><tr><td>South American sample areas</td><td>14,1</td><td>7</td><td>31</td><td>47.9</td></tr><tr><td>European sample areas</td><td>24</td><td>49.5</td><... | <table><tr><td></td><td colspan="4">Clusters</td></tr><tr><td></td><td>The comprehensive</td><td>The theoretician</td><td>The minimalist</td><td>The structural</td></tr></table> | <table><tr><td>South American sample areas</td><td>14,1</td><td>7</td><td>31</td><td>47.9</td></tr><tr><td>European sample areas</td><td>24</td><td>49.5</td><td>25</td><td>1,5</td></tr><tr><td>Total</td><td>21.4</td><td>38.4</td><td>26.6</td><td>13.7</td></tr></table> |
e23320a09c944bd0157e5bfc81e60300e590b3a2e8bd24a44d1598721686430b.png | simple | <table><tr><td>Resection margin</td><td>Recurrence rate No. patients (%)</td><td>Surgery and radiotherapy No. (%)</td><td>Surgery alone No. (%)</td></tr><tr><td>R0</td><td>5/16 (31)</td><td>2/4 (50)</td><td>3/12 (25)</td></tr><tr><td>R1</td><td>30/47 (64)</td><td>27/36 (75)</td><td>3/11 (27)</td></tr><tr><td>R2</td><td... | <table><tr><td>Resection margin</td><td>Recurrence rate No. patients (%)</td><td>Surgery and radiotherapy No. (%)</td><td>Surgery alone No. (%)</td></tr><tr><td>R0</td><td>5/16 (31)</td><td>2/4 (50)</td><td>3/12 (25)</td></tr><tr><td>R1</td><td>30/47 (64)</td><td>27/36 (75)</td><td>3/11 (27)</td></tr></table> | <table><tr><td>R2</td><td>11/20 (55)</td><td>9/14 (64)</td><td>2/6 (33)</td></tr><tr><td>R3</td><td>7/13 (54)</td><td>5/7 (71)</td><td>2/6 (33)</td></tr><tr><td>RX</td><td>7/14 (50)</td><td>5/7 (71)</td><td>2/7 (29)</td></tr></table> |
75e467cba65d6580a1e75e87e6ee763948ebc348c58f40957c4ce29359a7ccb1.png | simple | <table><tr><td> </td><td>Phase</td><td>Morphology</td><td>Secondary phase</td></tr><tr><td>1,098 K/8 h</td><td> </td><td> </td><td> </td></tr><tr><td> Undoped</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 0.5% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td> 1% Co</td><td>Rutile</td><td>Nanoro... | <table><tr><td></td><td>Phase</td><td>Morphology</td><td>Secondary phase</td></tr><tr><td>1,098 K/8 h</td><td></td><td></td><td></td></tr><tr><td>Undoped</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>0.5% Co</td><td>Rutile</td><td>Nanorod</td><td>-</td></tr><tr><td>1% Co</td><td>Rutile</td><td>Nanorod</td><... | <table><tr><td></td><td>Phase</td><td>Morphology</td><td>Secondary phase</td></tr><tr><td>/8 h</td><td>utile</td><td>particle</td><td></td></tr><tr><td>2 h/1,098 K</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><td>8 h/1,098 K</td><td>Rutile + anatase</td><td>Nanoparticle</td><td>-</td></tr><tr><t... |
ffc86d2823847f057b5e4f94142ca6976449e8f366a40edbcec5bb02f5fc13f5.png | simple | <table><tr><td></td><td>Men (<i>n</i> = 123)</td><td>Women (<i>n</i> = 169)</td><td>Total (<i>n</i> = 292)</td></tr><tr><td>Non-smokers, <i>n</i> (%)</td><td>47 (38.2)</td><td>74 (43.8)</td><td>121 (41.4)</td></tr><tr><td>Ever-smokers, <i>n</i> (%)</td><td>76 (61.8)</td><td>95 (56.2)</td><td>171 (58.6)</td></tr><tr><td... | <table><tr><td></td><td>Men (n = 123)</td><td>Women (n = 169)</td><td>Total (n = 292)</td></tr><tr><td>Non-smokers, n (%)</td><td>47 (38.2)</td><td>74 (43.8)</td><td>121 (41.4)</td></tr><tr><td>Ever-smokers, n (%)</td><td>76 (61.8)</td><td>95 (56.2)</td><td>171 (58.6)</td></tr><tr><td>1 positive SPT reaction, n (%)</td... | <table><tr><td>ic rhinoconjunctivitis (ARC), n (%)</td><td>2.5)</td><td>(42.0)</td><td>)</td></tr><tr><td>Family history of asthma, n (%)</td><td>17 (13.8)</td><td>36 (21.3)</td><td>53 (18.2)</td></tr><tr><td>Physician-diagnosed asthma, n (%)</td><td>7 (5.7)</td><td>6 (3.6)</td><td>13 (4.5)</td></tr><tr><td>Asthma medi... |
6f383440da897e7c34cd1524500ff2b8c5830511982d07f4397eec98075cb1c6.png | simple | <table><tr><td>Question number</td><td>Question</td></tr><tr><td>1.</td><td>Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant).</td></tr><tr><td>2.</td><td>Please tell me about how your shoulder tea... | <table><tr><td>Question number</td></tr><tr><td>1.</td></tr><tr><td>2.</td></tr><tr><td>3.</td></tr><tr><td>4.</td></tr></table> | <table><tr><td>Question</td></tr><tr><td>Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant).</td></tr><tr><td>Please tell me about how your shoulder tear affected/affects you? (follow up questions t... |
20d0ef8b8fb19928f950c22ae20f7aeb93bd7f4b5c4cb36025ae204a36f66c01.png | simple | <table><tr><td>Event</td><td>Grade 1 (0)</td><td>Grade 2 (1–2)</td><td>Grade 3 (3–6)</td><td>Grade 4 (> 6)</td><td>Na</td></tr><tr><td>Head lifting (n)</td><td>153 (88.4%)</td><td>5 (2.9%)</td><td>4 (2.3%)</td><td>6 (3.5%)</td><td>5 (2.9%)</td></tr><tr><td>Paddling (one limb) (n)</td><td>159 (91.9%)</td>... | <table><tr><td>Event</td><td>Grade 1 (0)</td><td>Grade 2 (1–2)</td><td>Grade 3 (3–6)</td><td>Grade 4 (> 6)</td><td>Na</td></tr><tr><td>Head lifting (n)</td><td>153 (88.4%)</td><td>5 (2.9%)</td><td>4 (2.3%)</td><td>6 (3.5%)</td><td>5 (2.9%)</td></tr><tr><td>Paddling (one limb) (n)</td><td>159 (91.9%)</td><td>8 (4.6%)</t... | <table><tr><td>Event</td><td>Grade 1 (0)</td><td>Grade 2 (1–2)</td><td>Grade 3 (3–6)</td><td>Grade 4 (> 6)</td><td>Na</td></tr><tr><td>Pull up (one limb) (n)</td><td>136 (78.6%)</td><td>23 (13.3%)</td><td>9 (5.2%)</td><td>0</td><td>5 (2.9%)</td></tr><tr><td>Pull up (several limbs) (n)</td><td>154 (89.0%)</td><td>13 (7.... |
e06f0286dfc72e1572a10b1bde12497d365ca297d9ab5dc766f0d5af9d9e40d2.png | simple | <table><tr><td>Generic name</td><td>Trade name</td><td>Number of cases of monotherapy</td></tr><tr><td>Losartan</td><td>Nu-lotan®</td><td>214</td></tr><tr><td>Valsartan</td><td>Diovan®</td><td>266</td></tr><tr><td>Telmisartan</td><td>Micardis®</td><td>185</td></tr><tr><td>Candesartan</td><td>Blopress... | <table><tr><td>Generic name</td><td>Trade name</td><td>Number of cases of monotherapy</td></tr><tr><td>Losartan</td><td>Nu-lotan®</td><td>214</td></tr><tr><td>Valsartan</td><td>Diovan®</td><td>266</td></tr></table> | <table><tr><td>Telmisartan</td><td>Micardis®</td><td>185</td></tr><tr><td>Candesartan</td><td>Blopress®</td><td>458</td></tr><tr><td>Olmesartan</td><td>Olmetec®</td><td>192</td></tr></table> |
e2e32c476d940941003dc1b874aac51ba628fa877458796425abdb2c8961895a.png | simple | <table><tr><td>Parameter</td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td>Level 4</td><td>Level 5</td></tr><tr><td>100-OD (% sat.)</td><td>≤10</td><td>≤20</td><td>≤30</td><td>≤50</td><td>>50</td></tr><tr><td>BOD<sub>5</sub> (O<sub>2</sub> mg/L)</td><td><2.5</td><td>≤4</td><td>... | <table><tr><td>Parameter</td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td>Level 4</td><td>Level 5</td></tr><tr><td>100-OD (% sat.)</td><td>≤10</td><td>≤20</td><td>≤30</td><td>≤50</td><td>>50</td></tr><tr><td>BOD5 (O2 mg/L)</td><td><2.5</td><td>≤4</td><td>≤8</td><td>≤15</td><td>>15</td></tr><tr><td>COD (O2 mg/L)<... | <table><tr><td>Parameter</td><td>Level 1</td><td>Level 2</td><td>Level 3</td><td>Level 4</td><td>Level 5</td></tr><tr><td>Escherichia coli (UFC/100/mL)</td><td>0</td><td>.000</td><td></td><td></td><td>0.000</td></tr><tr><td>Score to be attributed for each analysed parameter (75° percentile of the monitoring period)</td... |
6a0794db078e4abb0e1f784a6a84828b3c5f0c663a4a459535891903ee78d177.png | complex | <table><tr><td>Re-revision diagnosis</td><td colspan="2">UKA to UKA minor</td><td colspan="2">UKA to UKA major</td><td colspan="2">UKA to TKA</td><td colspan="2">TKA to TKA</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Loosening/lysis</td><td>17</td><... | <table><tr><td>Re-revision diagnosis</td><td colspan="2">UKA to UKA minor</td><td colspan="2">UKA to UKA major</td><td colspan="2">UKA to TKA</td><td colspan="2">TKA to TKA</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Loosening/lysis</td><td>17</td><... | <table><tr><td>Re-revision diagnosis</td><td colspan="2">UKA to UKA minor</td><td colspan="2">UKA to UKA major</td><td colspan="2">UKA to TKA</td><td colspan="2">TKA to TKA</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Pain</td><td>6</td><td>16.2</td>... |
10731fdc0c192a221a4a2cddfd60e3a57f1d5df481b23fc1b7d8781f3f5b8a8b.png | complex | <table><tr><td>Diagnosis in MRI</td><td>Specific abnormalities in MRI</td><td><i>N</i></td><td>Total number (%)</td></tr><tr><td>Abnormal MRI</td><td> </td><td> </td><td>13 (52%)</td></tr><tr><td rowspan="2">Hepatic dysmorphia</td><td>Included lobulation of liver surface</td><td>3</td><td rowspan="2">3 (12%)</td></tr><... | <table><tr><td>Diagnosis in MRI</td><td>Specific abnormalities in MRI</td><td>N</td><td>Total number (%)</td></tr><tr><td>Abnormal MRI</td><td></td><td></td><td>13 (52%)</td></tr><tr><td rowspan="2">Hepatic dysmorphia</td><td>Included lobulation of liver surface</td><td>3</td><td rowspan="2">3 (12%)</td></tr><tr><td>In... | <table><tr><td>Diagnosis in MRI</td><td>Total number (%)</td></tr><tr><td>Total</td><td>25 (100%)</td></tr></table> |
d6262c934d811551f3a5e04ce8d29c5e590e7b6b90f56b1b703c225426f06e50.png | simple | <table><tr><td>Variable</td><td>OR [95%CI]</td><td>P value</td></tr><tr><td>Steroids before ICU stay</td><td>0.77 [0.17-3.49]</td><td>0.74</td></tr><tr><td>Steroids during ICU stay</td><td> </td><td> </td></tr><tr><td>No Steroid</td><td>5.64 [0.70-45.5]</td><td> </td></tr><tr><td>Low Dose Steroid</td><td>1</td><td>0.02... | <table><tr><td>Variable</td><td>OR [95%CI]</td><td>P value</td></tr><tr><td>Steroids before ICU stay</td><td>0.77 [0.17-3.49]</td><td>0.74</td></tr><tr><td>Steroids during ICU stay</td><td></td><td></td></tr><tr><td>No Steroid</td><td>5.64 [0.70-45.5]</td><td></td></tr><tr><td>Low Dose Steroi</td><td>1</td><td></td></t... | <table><tr><td>d</td><td></td><td>0.02</td></tr><tr><td>High Dose Steroids</td><td>9.33 [1.97-44.3]</td><td></td></tr><tr><td>SAPS II per point</td><td>1.04 [1.01-1.08]</td><td>0.01</td></tr><tr><td>Underlying disease</td><td></td><td></td></tr><tr><td>Hematological disease</td><td>1</td><td></td></tr><tr><td>Other</td... |
0f9d96f0b72e8d74928ed223907880e61d0b0d4b295cd37a42eb78de678c8b3d.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">Male</td><td colspan="3">Female</td></tr><tr><td>C</td><td>NC</td><td><i>p</i>-value</td><td>C</td><td>NC</td><td><i>p</i>-value</td></tr><tr><td>Dietary component</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Energy (kJ)</td><td>9665</td><td>986... | <table><tr><td rowspan="2"></td><td>Male</td></tr><tr><td>C</td></tr><tr><td>Dietary component</td><td></td></tr><tr><td>Energy (kJ)</td><td>9665</td></tr><tr><td>Nutrients</td><td></td></tr><tr><td>Carbohydrates (%E)</td><td>42.8</td></tr><tr><td>Total Sugars (%E)</td><td>18.1</td></tr><tr><td>Free Sugar (%E)</td><td>... | <table><tr><td colspan="2">Male</td><td colspan="3">Female</td></tr><tr><td>NC</td><td>p-value</td><td>C</td><td>NC</td><td>p-value</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>9863</td><td>0.1573</td><td>7238</td><td>7408</td><td>0.0684</td></tr><tr><td></td><td></td><td></td><td></td><td></t... |
c2c7c821612ce295ebf8553c1f2f9f04fbd1eedbb8499e03049ce0030013e504.png | simple | <table><tr><td>Variablea</td><td>HR (95% CI)</td><td><i>P</i></td></tr><tr><td>Bowel obstruction/perforation (positive vs negative)</td><td>4.118 (2.270-7.471)</td><td><.001</td></tr><tr><td>Lymphovascular invasion (positive vs negative)</td><td>1.766 (1.156-2.697)</td><td>.009</td></tr><tr><td>Five-gene molecular s... | <table><tr><td>Variablea</td><td>HR (95% CI)</td><td>P</td></tr><tr><td>Bowel obstruction/perforation (positive vs negative)</td><td>4.118 (2.270-7.471)</td><td><.001</td></tr></table> | <table><tr><td>Variablea</td><td>HR (95% CI)</td><td>P</td></tr><tr><td>Lymphovascular invasion (positive vs negative)</td><td>1.766 (1.156-2.697)</td><td>.009</td></tr><tr><td>Five-gene molecular signature (high-risk vs low-risk for 36-mo recurrence)</td><td>1.644 (1.035-2.610)</td><td>.035</td></tr></table> |
9e98077623fc16c7449c488bcf030ef762905d066651c779620c12c47f89bd47.png | simple | <table><tr><td>Subject</td><td>R (mean ± std. deviation)</td></tr><tr><td>1</td><td>0.8084 ± 0.0140</td></tr><tr><td>2</td><td>0.7605 ± 0.1104</td></tr><tr><td>3</td><td>0.7915 ± 0.0147</td></tr><tr><td>4</td><td>0.8045 ± 0.0173</td></tr><tr><td>5</td><td>0.7970 ± 0.0204</td></tr></table> | <table><tr><td>Subject</td><td>R (mean ± std. deviation)</td></tr><tr><td>1</td><td>0.8084 ± 0.0140</td></tr></table> | <table><tr><td>Subject</td><td>R (mean ± std. deviation)</td></tr><tr><td>2</td><td>0.7605 ± 0.1104</td></tr><tr><td>3</td><td>0.7915 ± 0.0147</td></tr><tr><td>4</td><td>0.8045 ± 0.0173</td></tr><tr><td>5</td><td>0.7970 ± 0.0204</td></tr></table> |
318ab7b48e1d03e83ed69b86c9d5420be14cfb5142ac491330000d1f6019738c.png | complex | <table><tr><td>% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:</td><td>% area change</td><td>% velocity change</td><td>% flow change</td></tr><tr><td rowspan="2">Healthy: Mean Coronary Wall Thickness</td><td><i>R</i> = -0.17</td><td><i>R</i> = 0.02</td><td><i>R</i> = -0.02</td></tr><tr><td><i>P</i> =... | <table><tr><td>% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:</td><td>% area change</td><td>% velocity change</td><td>% flow change</td></tr><tr><td rowspan="2">Healthy: Mean Coronary Wall Thickness</td><td>R = -0.17</td><td>R = 0.02</td><td>R = -0.02</td></tr><tr><td>P = 0.46</td><td>P = 0.93</td><... | <table><tr><td>% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:</td><td>% area change</td><td>% velocity change</td><td>% flow change</td></tr><tr><td>Healthy: Eccentricity Index</td><td>P = 0.46</td><td>P = 0.74</td><td>P = 0.56</td></tr><tr><td rowspan="2">CAD: Mean Coronary Wall Thickness</td><td>R... |
6a2464423d34de68930744a48e292631e1dd45543601c31834fa860cf5856b02.png | complex | <table><tr><td rowspan="3">Survey Data</td><td colspan="2">Model 1–30 min/day</td><td colspan="2">Model 2–60 min/day</td><td colspan="4">Model 3 – KKD</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2"><i>Active</i> vs <i>Inactive</i></td><td colspan="2"><i>Moderately Active</i> vs <i>In... | <table><tr><td rowspan="3">Survey Data</td><td colspan="2">Model 1–30 min/day</td><td colspan="2">Model 2–60 min/day</td><td colspan="4">Model 3 – KKD</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Active vs Inactive</td><td colspan="2">Moderately Active vs Inactive</td></tr><tr><td>Fixed effect (95% ... | <table><tr><td>Male</td><td colspan="2">1.87 (1.74, 2.00)</td><td>1.88 (1.80, 1.95)</td><td></td><td>2.26 (2.10, 2.43)</td><td></td><td>1.29 (1.20, 1.39)</td><td></td></tr><tr><td colspan="9">BMI status</td></tr><tr><td>Healthy weight</td><td>Referent</td><td>0.0007</td><td>Referent</td><td>0.0006</td><td>Referent</td>... |
a56b85e332f7f96fcd9850a8fe0dfb90a9f8748e61a88def87f5f22752e85c14.png | simple | <table><tr><td> </td><td>GOLD II</td><td>GOLD III</td><td>GOLD IV</td><td>Total</td></tr><tr><td> </td><td>(n = 12)</td><td>(n = 21)</td><td>(n = 10)</td><td>(n = 43)</td></tr><tr><td>Short acting bronchodilator</td><td>75.0%</td><td>80.9%</td><td>80.0%</td><td>79.1%</td></tr><tr><td>Combined LABA with steroid</td><td>... | <table><tr><td></td><td>GOLD II</td><td>GOLD III</td><td>GOLD IV</td><td>Total</td></tr><tr><td></td><td>(n = 12)</td><td>(n = 21)</td><td>(n = 10)</td><td>(n = 43)</td></tr></table> | <table><tr><td>Short acting bronchodilator</td><td>75.0%</td><td>80.9%</td><td>80.0%</td><td>79.1%</td></tr><tr><td>Combined LABA with steroid</td><td>58.3%</td><td>61.9%</td><td>70.0%</td><td>62.8%</td></tr><tr><td>Antibiotics</td><td>58.3%</td><td>61.9%</td><td>60.0%</td><td>60.5%</td></tr><tr><td>Expectorants</td><t... |
dc2990f6786ed9b47af01a5071897fbd3e55a5db4554e90b007e2408500608f4.png | complex | <table><tr><td>Adipokine</td><td colspan="2">Study time point</td><td>Media alone</td><td>Stimulated</td><td><i>P</i> values</td></tr><tr><td rowspan="4">Adipsin</td><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>3.83 (2.12)</td><td>4.74 (3.89)</td><td>0.743 (ns)</td></tr><tr><td>Range</td><td>0–23.14</td><td... | <table><tr><td>Adipokine</td></tr><tr><td rowspan="4">Adipsin</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">MCP-1</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">IL-1β</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">IP-10</td></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="4">CXCL8</td></tr><... | <table><tr><td colspan="2">Study time point</td><td>Media alone</td><td>Stimulated</td><td>P values</td></tr><tr><td rowspan="2">Pre-int</td><td>Mean (SEM)</td><td>3.83 (2.12)</td><td>4.74 (3.89)</td><td>0.743 (ns)</td></tr><tr><td>Range</td><td>0–23.14</td><td>0–57.72</td><td></td></tr><tr><td rowspan="2">Post-int</td... |
441eb1c54a2f03d7a83523765491f3808cb5d892dbaceed1350067e33fb87282.png | complex | <table><tr><td>Grade</td><td colspan="3">Normal group</td><td colspan="8">Osteoarthritis group</td></tr><tr><td></td><td>12 F</td><td>39 F</td><td>43 M</td><td>42 M</td><td>49 F</td><td>54 F</td><td>55 M</td><td>58 F</td><td>65 F</td><td>66 F</td><td>70 F</td></tr><tr><td>Transverse section</td><td>0</td><td>0</td><td>... | <table><tr><td>Grade</td><td colspan="3">Normal group</td><td colspan="8">Osteoarthritis group</td></tr><tr><td></td><td>12 F</td><td>39 F</td><td>43 M</td><td>42 M</td><td>49 F</td><td>54 F</td><td>55 M</td><td>58 F</td><td>65 F</td><td>66 F</td><td>70 F</td></tr><tr><td>Transverse se</td><td>0</td><td></td><td>0</td>... | <table><tr><td>ction</td><td></td><td>0</td><td></td><td></td><td></td><td>3</td><td></td><td></td><td></td><td>4</td><td></td></tr><tr><td>Longitudinal section</td><td>0</td><td>0</td><td>0</td><td>3</td><td>1</td><td>3</td><td>3</td><td>1</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Averagea</td><td>0</td><td>0</td... |
fe4947d31561efd4455d129c81aa3fa9eae1087c0acf9a6ad6019c903c49a11f.png | simple | <table><tr><td>Variable</td><td>Comparison used in rate ratio</td><td>Rate ratio (other death/HIV/TB death)</td><td>95% Confidence interval (<i>p</i> value)</td></tr><tr><td>Sex</td><td>Male/female</td><td>1.12</td><td>0.99–1.27 (0.077)</td></tr><tr><td>Country of origin</td><td>South Africa/Mozambique</td><td>0.... | <table><tr><td>Variable</td><td>Comparison used in rate ratio</td><td>Rate ratio (other death/HIV/TB death)</td><td>95% Confidence interval (p value)</td></tr></table> | <table><tr><td>Sex</td><td>Male/female</td><td>1.12</td><td>0.99–1.27 (0.077)</td></tr><tr><td>Country of origin</td><td>South Africa/Mozambique</td><td>0.85</td><td>0.75–0.98 (0.023)</td></tr><tr><td>Residence status</td><td>Temporary/permanent</td><td>1.05</td><td>0.91–1.21 (0.493)</td></tr><tr><td>Distance from Bhub... |
afb3f9e5bd4f871f1d3b263a3e2e79aa62313b08f41ba94b092294f589822ae3.png | complex | <table><tr><td colspan="2">ABRA system delayed closure system</td></tr><tr><td>Pros</td><td>Cons</td></tr><tr><td>ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequ... | <table><tr><td colspan="2">ABRA system delayed closure system</td></tr><tr><td>Pros</td><td>Cons</td></tr><tr><td>ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequ... | <table><tr><td>osure</td><td>he possibility to need to be used in conjunction with another dressing system</td></tr><tr><td>The changes of VAC system and time in nurse and surgery cares are more expensive than ABRA system</td><td>There is no active removal of the fluids. So if the peritonitis is still active a dressing... |
f4064b9fdbc7cce1191133eebba77c9db43fd93e5ef4f88585979e6da361816d.png | simple | <table><tr><td>Origin</td><td>Prenatal</td><td>Delivery room</td></tr><tr><td>Greek</td><td>34/2467 (1.4%)</td><td>3/174 (1.7%)</td></tr><tr><td>Albanian</td><td>20/227 (8.8%)</td><td>6/61 (9.8%)</td></tr><tr><td>Others*</td><td>11/135 (8.1%)</td><td>2/27 (7.4%)</td></tr><tr><td>Total</td><td>65/2829 (2.3%)**</td><td>1... | <table><tr><td>Origin</td><td>Prenatal</td><td>Delivery room</td></tr><tr><td>Greek</td><td>34/2467 (1.4%)</td><td>3/174 (1.7%)</td></tr><tr><td>A</td><td>2</td><td>6/61 (9.8%</td></tr></table> | <table><tr><td>Origin</td><td>Prenatal</td><td>Delivery room</td></tr><tr><td>lbanian</td><td>0/227 (8.8%)</td><td>)</td></tr><tr><td>Others*</td><td>11/135 (8.1%)</td><td>2/27 (7.4%)</td></tr><tr><td>Total</td><td>65/2829 (2.3%)**</td><td>11/262 (4.2%)**</td></tr></table> |
b0817948de46d0b3c6551eaebc4dd0fa5b3fb6c4b03315a7a191845effd24884.png | simple | <table><tr><td>Study characteristics</td><td>Nepal trial*</td><td>Bangladesh trial</td><td>Pakistan trial</td></tr><tr><td>Type of study</td><td>Cluster RCT</td><td>Cluster RCT</td><td>2 × 2 factorial design cluster RCT</td></tr><tr><td>No. clusters (average size)</td><td>413 (700)</td><td>133 (4100)</td><td>187 (... | <table><tr><td>Study characteristics</td></tr><tr><td>Type of study</td></tr><tr><td>No. clusters (average size)</td></tr><tr><td>Sample size total</td></tr><tr><td>Average sample size per group</td></tr><tr><td>Duration of trial</td></tr><tr><td>Overall NMR</td></tr><tr><td>% of home births</td></tr><tr><td>Inclusion ... | <table><tr><td>Nepal trial*</td><td>Bangladesh trial</td><td>Pakistan trial</td></tr><tr><td>Cluster RCT</td><td>Cluster RCT</td><td>2 × 2 factorial design cluster RCT</td></tr><tr><td>413 (700)</td><td>133 (4100)</td><td>187 (1000)</td></tr><tr><td>15,123</td><td>29,760</td><td>9,741</td></tr><tr><td>~ 5,050</td><td>~... |
145b658c4b48cbc5eb6ee5a81f6b081a4f8504427ce2ea7d2e7479b3869c280a.png | complex | <table><tr><td></td><td colspan="2">WHO guideline<sup>a</sup></td><td colspan="2">Swiss TPH guideline<sup>a</sup></td></tr><tr><td></td><td><i>Trichuris trichiura</i></td><td><i>Ascaris lumbricoides</i></td><td><i>Trichuris trichiura</i></td><td><i>Ascaris lumbricoides</i></td></tr><tr><td>Total number of Kato-Katz thi... | <table><tr><td></td><td colspan="2">WHO guidelinea</td><td colspan="2">Swiss TPH guidelinea</td></tr><tr><td></td><td>Trichuris trichiura</td><td>Ascaris lumbricoides</td><td>Trichuris trichiura</td><td>Ascaris lumbricoides</td></tr></table> | <table><tr><td>Total number of Kato-Katz thick smears (positive/negative)</td><td>1,445 (1,189/256)</td><td>1,445 (297/1,148)</td><td>1,445 (1,189/256)</td><td>1,445 (297/1,148)</td></tr><tr><td>1. No. of Kato-Katz thick smears with difference in FECs (%)</td><td>345 (23.9%)</td><td>148 (10.2%)</td><td>97 (6.7%)</td><t... |
6abf16cd0b41fb3a390497ed183cfe53079fb71f04fb53f6ea5fc44157f086bf.png | complex | <table><tr><td rowspan="2">Biologics</td><td colspan="3">Pooled incremental efficacy</td><td colspan="3">6-month incremental cost-effectiveness ratio</td></tr><tr><td>Base case</td><td>Best case </td><td>Worst case</td><td>Base case</td><td>Best case</td><td>Worst case </td></tr><tr><td>Etanercept</td><td>58%</td><td>7... | <table><tr><td rowspan="2">Biologics</td><td colspan="3">Pooled incremental efficacy</td></tr><tr><td>Base case</td><td>Best case</td><td>Worst case</td></tr><tr><td>Etanercept</td><td>58%</td><td>71%</td><td>45%</td></tr><tr><td>Adalimumab</td><td>56%</td><td>59%</td><td>52%</td></tr><tr><td>Infliximab</td><td>69%</td... | <table><tr><td colspan="3">6-month incremental cost-effectiveness ratio</td></tr><tr><td>Base case</td><td>Best case</td><td>Worst case</td></tr><tr><td>$30,954</td><td>$25,287</td><td>$39,897</td></tr><tr><td>$23,980</td><td>$22,760</td><td>$25,824</td></tr><tr><td>$28,587</td><td>$25,954</td><td>$31,310</td></tr><tr>... |
5f6efd8a98a9d3a8efa8db04b6c10aa609213228e12e9d16fcfef1390f330e92.png | complex | <table><tr><td colspan="2">Architecture</td><td>DeepLab without CRF (Chen et al., 2014)</td><td>FCN (Long et al., 2015)</td><td>U-Net (Ronneberger et al., 2015)</td><td>DeconvNet (Noh et al., 2015)</td></tr><tr><td colspan="2">Side length of receptive field</td><td>44</td><td>52</td><td>46</td><td>44</td></tr><tr><td r... | <table><tr><td colspan="2">Architecture</td><td>DeepLab without CRF (Chen et al., 2014)</td><td>FCN (Long et al., 2015)</td><td>U-Net (Ronneberger et al., 2015)</td><td>DeconvNet (Noh et al., 2015)</td></tr><tr><td colspan="2">Side length of receptive field</td><td>44</td><td>52</td><td>46</td><td>44</td></tr><tr><td r... | <table><tr><td rowspan="2"></td><td>l</td><td>3</td><td>84</td><td></td><td>11</td></tr><tr><td>test</td><td>4.08</td><td>3.66</td><td>4.17</td><td>3.58</td></tr><tr><td rowspan="3">DR</td><td>train</td><td>0.97</td><td>0.99</td><td>0.99</td><td>0.99</td></tr><tr><td>val</td><td>0.98</td><td>0.99</td><td>0.99</td><td>0... |
881dc21d1cb9252d760f00d67998f553edca3f1665832524d94c9b27eae25418.png | complex | <table><tr><td></td><td colspan="3">All suicide</td><td colspan="3">Firearm suicide</td><td colspan="3">Nonfirearm suicide</td></tr><tr><td></td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td></tr><tr><td>Crude analyses</td><td></td><t... | <table><tr><td></td><td colspan="3">All suicide</td><td colspan="3">Firearm suicide</td><td colspan="3">Nonfirearm suicide</td></tr><tr><td></td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td><td>IRR*</td><td>95% CI</td><td>P-value</td></tr></table> | <table><tr><td>Crude analyses</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NonTCA^:TCA ratio</td><td>0.85</td><td>(0.76, 0.95)</td><td>0.0040</td><td>0.69</td><td>(0.57, 0.84)</td><td>0.0002</td><td>1.07</td><td>(0.96, 1.18)</td><td>0.2270</td></tr><tr><td>Multivaria... |
9322965dadc8a9a52fd5a7c5faa7d0b4d3d3d49ae7ea439b99080bf82ff05e04.png | simple | <table><tr><td> </td><td>Low-income countries</td><td>Middle-income countries</td><td>High-income countries</td></tr><tr><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Number of global countries where data is < 5% gross monthly income</td><td>5</td><td>78</td><td>46</td></tr><tr><td>% of subscriptions with bro... | <table><tr><td></td><td>Low-income countries</td><td>Middle-income countries</td><td>High-income countries</td></tr></table> | <table><tr><td></td><td></td><td></td><td></td></tr><tr><td>Number of global countries where data is < 5% gross monthly income</td><td>5</td><td>78</td><td>46</td></tr><tr><td>% of subscriptions with broadband speeds 10 mbps or higher</td><td>7</td><td>50</td><td>75</td></tr></table> |
e9d01862d3bdafff21ee423db8d43c950c69c544c86b6a98fcb0d2e3c2390fbe.png | simple | <table><tr><td>Variable</td><td>RBHS group (<i>n</i> = 36)</td><td>Control group (<i>n</i> = 38)</td><td><i>P</i>value</td></tr><tr><td>Composite outcome (any morbid event)</td><td>1 (2.8)</td><td>5 (13.1)</td><td>0.20</td></tr><tr><td>Morbid events<sup>a</sup></td><td> </td><td> </td><td> </td></tr><tr><td>Infection</... | <table><tr><td>Variable</td><td>RBHS group (n = 36)</td><td>Control group (n = 38)</td><td>Pvalue</td></tr></table> | <table><tr><td>Composite outcome (any morbid event)</td><td>1 (2.8)</td><td>5 (13.1)</td><td>0.20</td></tr><tr><td>Morbid eventsa</td><td></td><td></td><td></td></tr><tr><td>Infection</td><td>0 (0%)</td><td>1 (2.8%)</td><td>0.20</td></tr><tr><td>Thrombotic</td><td>1 (2.8%)</td><td>2 (5.3%)</td><td>0.87</td></tr><tr><td... |
654c68c317a8e166c351f5696c53739ea0216d723d9733c8cae47a5f3b2227db.png | simple | <table><tr><td>Country</td><td>Acronym of the Study</td><td>Year of Recruitment</td><td>Age Class</td><td><i>n</i></td><td>GM</td><td>50p</td><td>95p</td><td>Reference</td></tr><tr><td>Italy</td><td>SEpiAs</td><td>2010</td><td>20–44</td><td>271</td><td>8.76</td><td>7.78</td><td>86.28</td><td>[49]</td></tr><tr><td... | <table><tr><td>Country</td><td>Acronym of the Study</td><td>Year of Recruitment</td><td>Age Class</td><td>n</td><td>GM</td><td>50p</td><td>95p</td><td>Reference</td></tr><tr><td>Italy</td><td>SEpiAs</td><td>2010</td><td>20–44</td><td>271</td><td>8.76</td><td>7.78</td><td>86.28</td><td>[49]</td></tr><tr><td>Germany</td>... | <table><tr><td>Country</td><td>Acronym of the Study</td><td>Year of Recruitment</td><td>Age Class</td><td>n</td><td>GM</td><td>50p</td><td>95p</td><td>Reference</td></tr><tr><td>USA</td><td>NHANES</td><td>2009–20102011–2012</td><td>>20 years</td><td>20201724</td><td>6.75.6</td><td>5.955.15</td><td>23.217.6</td><td>[57]... |
ea1e6b33085e4c667c7e53f6fae6b8121c82a1ea38d0e19a1fd7dbd2191a9f28.png | simple | <table><tr><td>Data Set</td><td>Original</td><td>Global Median</td><td>Quantile</td><td>Cyclic Loess</td><td>IS.Median</td><td>Invariant Set</td></tr><tr><td>PSD</td><td>4.18% (1.96%)</td><td>2.15% (1.41%)</td><td>1.97% (1.12%)</td><td>2.12% (1.39%)</td><td>3.09% (1.51%)</td><td>1.99% (1.29%)</td></tr><tr><td>CSP</td><... | <table><tr><td>Data Set</td><td>Original</td><td>Global Median</td><td>Quantile</td><td>Cyclic Loess</td><td>IS.Median</td><td>Invariant Set</td></tr><tr><td>PSD</td><td>4.18% (1.96%)</td><td>2.15% (1.41%)</td><td>1.97% (1.12%)</td><td>2.12% (1.39%)</td><td>3.09% (1.51%)</td><td>1.99% (1.29%)</td></tr><tr><td>CSP</td><... | <table><tr><td>S. Pyogene</td><td>3.05% (2.78%)</td><td>3.47% (2.84%)</td><td>2.34% (2.02%)</td><td>2.85% (3.15%)</td><td>3.12% (3.32%)</td><td>2.69% (2.74%)</td></tr></table> |
4a742c470c67b5180dab320c5f43da5d4283917c4d0c3004c8edabb5a921548a.png | simple | <table><tr><td>Clinical indicators</td><td>OR (95 % CI)</td><td><i>p</i>-value</td><td>Multivariable OR (95 % CI)</td><td><i>p</i>-value</td></tr><tr><td>LDL-C goal attainment</td><td></td><td></td><td></td><td></td></tr><tr><td> LDL-C ≥ 100 mg/dL</td><td>1.00</td><td></td><td>1.00</td><td></td></tr><tr><td> LDL-... | <table><tr><td>Clinical indicators</td><td>OR (95 % CI)</td><td>p-value</td><td>Multivariable OR (95 % CI)</td></tr><tr><td>LDL-C goal attainment</td><td></td><td></td><td></td></tr><tr><td>LDL-C ≥ 100 mg/dL</td><td>1.00</td><td></td><td>1.00</td></tr><tr><td>LDL-C 70–99 mg/dL</td><td>0.75 (0.36–1.58)</td><td>0.448</td... | <table><tr><td>p-value</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>0.240</td></tr><tr><td><0.001</td></tr><tr><td>0.009</td></tr><tr><td><0.001</td></tr><tr><td>0.001</td></tr><tr><td>0.258</td></tr><tr><td>0.249</td></tr><tr><td>0.101</td></tr><tr><td>0.428</td></tr><tr><td>0.890</td></tr></table> |
3ffddc2eb3a94c219a38abf48d0b3018ee3c1a9728bf0c0fd4666188a0d930b9.png | complex | <table><tr><td>Function</td><td>Gene</td><td>Accession no.<sup>∗</sup></td><td colspan="2">Chromosome</td></tr><tr><td></td><td></td><td></td><td><i>T. aestivum</i></td><td><i>Ae. umbellulata</i></td></tr><tr><td>Protein biosynthesis</td><td></td><td></td><td></td><td></td></tr><tr><td>HMW glutenins</td><td>Glu-1... | <table><tr><td>Function</td><td>Gene</td><td>Accession no.∗</td><td colspan="2">Chromosome</td></tr><tr><td></td><td></td><td></td><td>T. aestivum</td><td>Ae. umbellulata</td></tr><tr><td>Protein biosynthesis</td><td></td><td></td><td></td><td></td></tr><tr><td>HMW glutenins</td><td>Glu-1Ax1</td><td>X61009</td><td>1A</... | <table><tr><td>γ-Gliadins</td><td>Group/pattern/subgroup</td><td></td><td></td><td></td></tr><tr><td></td><td>C10/C10-P1/SG-1</td><td>AJ937838.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P2/SG-2</td><td>AF234646.1</td><td>1DS</td><td>1U</td></tr><tr><td></td><td>C9/C9-P3/SG-3</td><td>FJ006638.1</td><td>1DS... |
dee34620c4a39b8a1a618328528c813e5b3176e81f5d82a936727bf51a862d6f.png | simple | <table><tr><td></td><td>RDP (<i>n</i> = 7)</td><td>LDP (<i>n</i> = 21)</td><td><i>P</i> value</td></tr><tr><td>Mean operative time (min)</td><td>368</td><td>210</td><td>0.0002</td></tr><tr><td>Mean blood loss (mL)</td><td>200</td><td>250</td><td>0.451</td></tr><tr><td>Transfusion (no. of patients) (%)</td><td>0</td><td... | <table><tr><td></td><td>RDP (n = 7)</td><td>LDP (n = 21)</td><td>P value</td></tr><tr><td>Mean operative time (min)</td><td>368</td><td>210</td><td>0.0002</td></tr><tr><td>Mean blood loss (mL)</td><td>200</td><td>250</td><td>0.451</td></tr><tr><td>Transfusion (no. of patients) (%)</td><td>0</td><td>0</td><td></td></tr>... | <table><tr><td>Conversion (no. of patients) (%)</td><td>0</td><td>0</td><td></td></tr><tr><td>Reverse operation (no. of patients) (%)</td><td>0</td><td>1 (4.7)a</td><td></td></tr><tr><td>Mean postoperative stay (days)</td><td>8.7</td><td>10.6</td><td>0.004</td></tr><tr><td>Complications (no. of patients) (%)</td><td>2 ... |
c56c1c831ace51c4e392411aa13a46bbefd3a729537a1fea3bfd01d72a73ea33.png | simple | <table><tr><td>Group</td><td>Drug</td><td>Frequency</td><td>Percent (n/N) <sup>b</sup></td></tr><tr><td>β-lactam</td><td></td><td>26</td><td>28.9 (26/90)</td></tr><tr><td> Penicillin</td><td>PenicillinG</td><td>11</td><td>29.0 (11/27)</td></tr><tr><td></td><td>Ampicillin</td><td>12</td><td>32.4 (12/26)</td></tr><t... | <table><tr><td>Group</td><td>Drug</td><td>Frequency</td><td>Percent (n/N) b</td></tr><tr><td>β-lactam</td><td></td><td>26</td><td>28.9 (26/90)</td></tr><tr><td>Penicillin</td><td>PenicillinG</td><td>11</td><td>29.0 (11/27)</td></tr><tr><td></td><td>Ampicillin</td><td>12</td><td>32.4 (12/26)</td></tr><tr><td>Cephalospor... | <table><tr><td>Aminoglycoside-lincosamide</td><td>Lincospectin</td><td>12</td><td>31.6 (12/26)</td></tr><tr><td>Macrolide</td><td>Tylosin</td><td>2</td><td>5.3 (2/36)</td></tr></table> |
b08069a254d02a29e242b1f148977fa3100aa37d0d898366a08ff3764f2f2f84.png | complex | <table><tr><td rowspan="2">Group</td><td rowspan="2">Dose (mg/kg)</td><td colspan="4">Mean Fasting Blood Sugar Level (mM)</td></tr><tr><td>0 min</td><td>30 min</td><td>60 min</td><td>120 min</td></tr><tr><td>NC</td><td>–</td><td>4.32 ± 0.88</td><td>13.65 ± 1.24</td><td>8.94 ± 1.47</td><td>4.89 ... | <table><tr><td rowspan="2">Group</td><td rowspan="2">Dose (mg/kg)</td><td colspan="4">Mean Fasting Blood Sugar Level (mM)</td></tr><tr><td>0 min</td><td>30 min</td><td>60 min</td><td>120 min</td></tr><tr><td>NC</td><td>–</td><td>4.32 ± 0.88</td><td>13.65 ± 1.24</td><td>8.94 ± 1.47</td><td>4.89 ± 0.95</td></tr></table> | <table><tr><td rowspan="2">Group</td><td rowspan="2">Dose (mg/kg)</td><td colspan="4">Mean Fasting Blood Sugar Level (mM)</td></tr><tr><td>0 min</td><td>30 min</td><td>60 min</td><td>120 min</td></tr><tr><td>MC</td><td>–</td><td>16.04 ± 2.15 **</td><td>48.65 ± 3.29 **</td><td>42.32 ± 4.18 **</td><td>32.74 ± 2.82 **</td... |
49ce65355e37577062f7b2ecc5572e2c83cf4597cc0ec5ce5e0d72cd8c9fe952.png | complex | <table><tr><td>Animal ID</td><td>Sex</td><td><i>M</i><sub>b</sub> (kg)</td><td>SL (cm)</td><td>G (cm)</td><td>[Hct]</td><td colspan="2">N</td><td colspan="2"><i>f</i><sub>R</sub> (breaths ⋅ min<sup>-1</sup>)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Air</td><td>Water</td><td>Air</td><... | <table><tr><td>Animal ID</td><td>Sex</td><td>Mb (kg)</td><td>SL (cm)</td><td>G (cm)</td><td>[Hct]</td><td colspan="2">N</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Air</td><td>Water</td></tr><tr><td>Tt19</td><td>M</td><td>294</td><td>256</td><td>142</td><td>54</td><td>104</td><td>17</td></tr>... | <table><tr><td colspan="2">fR (breaths ⋅ min-1)</td></tr><tr><td>Air</td><td>Water</td></tr><tr><td>3.9</td><td>4.7</td></tr><tr><td>5.8</td><td>9.7</td></tr><tr><td>6.1</td><td>9.6</td></tr><tr><td>4.4</td><td>3.0</td></tr><tr><td>5.1 ± 1.0</td><td>6.7 ± 3.4</td></tr></table> |
5b4729d229730eb04707971603b8a7559b32434812f4ee49e113a02e4a377b53.png | complex | <table><tr><td rowspan="2">Predictor</td><td colspan="4">1 year</td><td colspan="4">2 years</td></tr><tr><td>Unadjusted OR (95% CI)</td><td>p Value</td><td>Adjusted OR (95% CI)</td><td>p Value</td><td>Unadjusted OR (95% CI)</td><td>p Value</td><td>Adjusted OR (95% CI)</td><td>p Value</td></tr><tr><td>HAQ score</td><td>... | <table><tr><td rowspan="2">Predictor</td><td colspan="4">1 year</td><td colspan="2">2 years</td></tr><tr><td>Unadjusted OR (95% CI)</td><td>p Value</td><td>Adjusted OR (95% CI)</td><td>p Value</td><td>Unadjusted OR (95% CI)</td><td>p Value</td></tr><tr><td>HAQ score</td><td>1.84 (1.12 to 3.01)</td><td>0.02</td><td>1.87... | <table><tr><td colspan="2">2 years</td></tr><tr><td>Adjusted OR (95% CI)</td><td>p Value</td></tr><tr><td>1.42 (0.89 to 2.26)</td><td>0.14</td></tr></table> |
e20a62f2968f5a3b6096a5f6ce779091a58acd098fb53b99abffe5ef4eda4403.png | simple | <table><tr><td>Type</td><td>CVID (<i>n</i> = 34)</td><td>IgGSD (<i>n</i> = 398)</td><td>Value of <i>P</i></td></tr><tr><td>B∗07</td><td>29.4 (10)</td><td>22.9 (91)</td><td>0.3866</td></tr><tr><td>B∗08</td><td>38.2 (13)</td><td>25.4 (101)</td><td>0.1025</td></tr><tr><td>B∗13</td><td>0</td><td>4.3 (17)<... | <table><tr><td>Type</td><td>CVID (n = 34)</td><td>IgGSD (n = 398)</td><td>Value of P</td></tr><tr><td>B∗07</td><td>29.4 (10)</td><td>22.9 (91)</td><td>0.3866</td></tr><tr><td>B∗08</td><td>38.2 (13)</td><td>25.4 (101)</td><td>0.1025</td></tr><tr><td>B∗13</td><td>0</td><td>4.3 (17)</td><td>0.2414</td></tr><tr><td>B∗14</t... | <table><tr><td>B∗48</td><td>0</td><td>0.3 (1)</td><td>0.9213</td></tr><tr><td>B∗49</td><td>0</td><td>3.8 (15)</td><td>0.2863</td></tr><tr><td>B∗50</td><td>0</td><td>2.8 (11)</td><td>0.3705</td></tr><tr><td>B∗51</td><td>14.7 (5)</td><td>8.3 (33)</td><td>0.1673</td></tr><tr><td>B∗52</td><td>0</td><td>2.5 (10)</td><td>0.4... |
5876a56e841c3bf7f53a016c7bbe4635a7f206815d4b365a27cf67c8a6f57f1b.png | simple | <table><tr><td>Study Cohort</td><td>Number</td><td>Percentages</td></tr><tr><td>Women</td><td>36</td><td>34</td></tr><tr><td>Men</td><td>71</td><td>66</td></tr><tr><td>Mean Age 64.7 years</td><td></td><td></td></tr><tr><td>(Range 31–95 years)</td><td></td><td></td></tr><tr><td>Clinical Neuropathic Syndrome</td><t... | <table><tr><td>Study Cohort</td><td>Number</td><td>Percentages</td></tr><tr><td>Women</td><td>36</td><td>34</td></tr><tr><td>Men</td><td>71</td><td>66</td></tr><tr><td>Mean Age 64.7 years</td><td></td><td></td></tr><tr><td>(Range 31–95 years)</td><td></td><td></td></tr><tr><td>Clinical Neuropathic Syndrome</td><td></td... | <table><tr><td>Moderate</td><td>54</td><td>50</td></tr><tr><td>Severe</td><td>35</td><td>33</td></tr><tr><td>Teased Fiber/Semithin Section Analysis</td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td>1</td></tr><tr><td>Axonopathy</td><td>45</td><td>65</td></tr><tr><td>Myelinopathy</td><td>23</td><td>35</td></tr... |
2451c38c13d8d4146e1b0623a4cf77f006a9be0cc7e0ec98aa00f22dd7361c9b.png | simple | <table><tr><td>Type</td><td>Strain/<i> Transgene</i><sup>b</sup></td><td>Main pattern<sup>c</sup></td><td>Myoepithelial differentiation<sup>d</sup></td><td>EMT (%)<sup>e</sup></td><td>K1</td><td>K5</td><td>K6</td><td>K8/18</td><td>K10</td><td>K14</td><td>K17</td><td>FLG</td><td>IVL</td><td>LOR</td><td>THH</td><td>SMA</... | <table><tr><td>Type</td><td>Strain/ Transgeneb</td><td>Main patternc</td><td>Myoepithelial differentiationd</td><td>EMT (%)e</td><td>K1</td><td>K5</td><td>K6</td><td>K8/18</td><td>K10</td><td>K14</td><td>K17</td><td>FLG</td><td>IVL</td><td>LOR</td><td>THH</td><td>SMA</td><td>VIM</td></tr><tr><td>Simple</td><td>FVB-Myc<... | <table><tr><td>Strain/ Transgeneb</td><td>Main patternc</td><td>Myoepithelial differentiationd</td><td>EMT (%)e</td><td>K5</td><td>K8/18</td><td>K14</td><td>K17</td><td>VIM</td></tr><tr><td>FVB-Hras</td><td>Solid with EMT</td><td>3/4</td><td>3/4 (<1%)</td><td>+</td><td>++</td><td>+</td><td>+</td><td>+</td></tr></table> |
2ac2c322881f3d9db94e42ef4a4511c8b4121130b88ee846d58ef20c560a15f7.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">HAA intake</td><td></td></tr><tr><td>Low</td><td>Moderate</td><td>High</td><td><i>P</i><sub>interaction</sub></td></tr><tr><td colspan="5"><i>NAT2</i>-imputed phenotype</td></tr><tr><td> Rapid or intermediate acetylator</td><td></td><td></td><td></td><td></td></tr><tr><td... | <table><tr><td rowspan="2"></td><td colspan="3">HAA intake</td><td></td></tr><tr><td>Low</td><td>Moderate</td><td>High</td><td>Pinteraction</td></tr><tr><td colspan="5">NAT2-imputed phenotype</td></tr><tr><td>Rapid or intermediate acetylator</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/Controls</td><td>92... | <table><tr><td colspan="5">CYP1A2</td></tr><tr><td>CC</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases/controls</td><td>7/17</td><td>14/17</td><td>13/13</td><td></td></tr><tr><td>OR (95% CI)</td><td>1.00</td><td>2.05 (0.73–5.77)</td><td>2.65 (0.97–7.29)</td><td></td></tr><tr><td>CA + AA</td><td></td><td></td>... |
77ec8ea3f346616ea45d6fc366882b243a2aa12d55e7120ad7f96cc6626718f2.png | complex | <table><tr><td>EORTC QLQ-C30 subscales</td><td>Item</td><td colspan="4">Baseline</td><td colspan="4">2 weeks post-RT</td></tr><tr><td> </td><td> </td><td>IG (n = 89)</td><td>CON (n = 89)</td><td> </td><td> </td><td>IG (n = 89)</td><td>CON (n = 89)</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>Mean(SD)</td><t... | <table><tr><td>EORTC QLQ-C30 subscales</td><td>Item</td><td colspan="4">Baseline</td><td colspan="4">2 weeks post-RT</td></tr><tr><td></td><td></td><td>IG (n = 89)</td><td>CON (n = 89)</td><td></td><td></td><td>IG (n = 89)</td><td>CON (n = 89)</td><td></td><td></td></tr><tr><td></td><td></td><td>Mean(SD)</td><td>Mean(S... | <table><tr><td>Functioning scales</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Physical functioning PF</td><td>1-5</td><td>77.23(10.19)</td><td>78.91(10.81)</td><td>−1.067</td><td>0.288</td><td>79.70(9.80)</td><td>75.36(9.71)</td><td>2.970</td><td>0.003</td></tr><tr>... |
a4da6baf2a9f4a9ac6462c6e73f82d537be3fee669b49c8626929f23b1502b5b.png | simple | <table><tr><td></td><td>HUS-STEMI I</td><td>HUS-STEMI II</td><td></td></tr><tr><td></td><td>n = 194</td><td>n = 306</td><td></td></tr><tr><td></td><td>%</td><td>%</td><td>p</td></tr><tr><td>Mean age, mean (SD) years</td><td>64.8 (12.9)</td><td>64.3 (14.0)</td><td>0.920</td></tr><tr><td>Age > 75 years</td><td>23.7</t... | <table><tr><td></td><td>HUS-STEMI I</td><td>HUS-STEMI II</td><td></td></tr><tr><td></td><td>n = 194</td><td>n = 306</td><td></td></tr><tr><td></td><td>%</td><td>%</td><td>p</td></tr><tr><td>Mean age, mean (SD) years</td><td>64.8 (12.9)</td><td>64.3 (14.0)</td><td>0.920</td></tr><tr><td>Age > 75 years</td><td>23.7</td><... | <table><tr><td>Current smoker</td><td>35.6</td><td>39.0</td><td>0.449</td></tr><tr><td>Hypertension</td><td>63.4</td><td>53.3</td><td>0.026</td></tr><tr><td>Dyslipidemia</td><td>44.8</td><td>41.5</td><td>0.462</td></tr><tr><td>Renal dysfunction</td><td>1.5</td><td>4.2</td><td>0.094</td></tr><tr><td>AMI</td><td>18.6</td... |
e789d6cfa0348cfe1fe0186a8e1a8ef888b34d4c11ed4ee024474fc3d6a5929c.png | simple | <table><tr><td>Category</td><td>All Respondents (n = 769)</td><td>Nurses (n = 527)</td><td>Physicians (n = 238)</td></tr><tr><td>1 Lack of time<sup>a</sup></td><td>33.0% (254)</td><td>27.3% (144)</td><td>46.2% (110)</td></tr><tr><td>2 Behaviours attributed to women living with abuse</td><td>21.5% (165)</td><td>19.9% (1... | <table><tr><td>Category</td><td>All Respondents (n = 769)</td></tr><tr><td>1 Lack of timea</td><td>33.0% (254)</td></tr><tr><td>2 Behaviours attributed to women living with abuse</td><td>21.5% (165)</td></tr><tr><td>3 Lack of traininga</td><td>16.4% (126)b</td></tr><tr><td>4 Language/cultural practicesa</td><td>15.5% (... | <table><tr><td>Nurses (n = 527)</td><td>Physicians (n = 238)</td></tr><tr><td>27.3% (144)</td><td>46.2% (110)</td></tr><tr><td>19.9% (105)</td><td>25.2% (60)</td></tr><tr><td>20.9% (110)</td><td>5.5% (13)</td></tr><tr><td>18.4% (97)</td><td>8.8% (21)</td></tr><tr><td>19.5% (103)</td><td>2.1% (5)</td></tr><tr><td>10.4% ... |
20156a01ac3d3b8991a93774f5666df81ea8ddb231b41645d932e8a108c289d5.png | simple | <table><tr><td><i>CHEK2 </i>mutation type</td><td>Controls(<i>n </i>= 1,026)<sup>a</sup></td><td>Allelic frequency in controls</td><td>Cases(<i>n </i>= 1,014)<sup>a</sup></td><td>Allelic frequency in cases</td><td>P value</td><td>OR</td><td>95% CI</td></tr><tr><td>Any <i>CHEK2 </i>mutation</td><td>4</td><td>0.39%</td><... | <table><tr><td>CHEK2 mutation type</td></tr><tr><td>Any CHEK2 mutation</td></tr><tr><td>CHEK2 deleterious mutations</td></tr></table> | <table><tr><td>Controls(n = 1,026)a</td><td>Allelic frequency in controls</td><td>Cases(n = 1,014)a</td><td>Allelic frequency in cases</td><td>P value</td><td>OR</td><td>95% CI</td></tr><tr><td>4</td><td>0.39%</td><td>16</td><td>1.58%</td><td>0.0065</td><td>4.15</td><td>(1.38 to 12.50)</td></tr><tr><td>3</td><td>0.29%<... |
34f5bf2176f57cb9e66cb401cb5fdf678bd09c332d50efd8955dc46b41a953a9.png | simple | <table><tr><td>Chr</td><td>SNP</td><td>Position</td><td>Minor allele/major allele</td><td>Association <i>p</i>-value</td><td>Allelic OR (95% CI)</td><td>Bonferroni adjusted <i>p</i>-value</td><td>BH-false discovery rate <i>p</i>-value</td><td>Interaction (ADD × sex) <i>p</i>-value</td></tr><tr><td>1</td><td>rs8656... | <table><tr><td>Chr</td><td>SNP</td><td>Position</td><td>Minor allele/major allele</td><td>Association p-value</td><td>Allelic OR (95% CI)</td><td>Bonferroni adjusted p-value</td><td>BH-false discovery rate p-value</td><td>Interaction (ADD × sex) p-value</td></tr><tr><td>1</td><td>rs865682</td><td>223,080,777</td><td>A/... | <table><tr><td>11</td><td>rs761453</td><td>31,834,576</td><td>A/G</td><td>3.867 × 10-5</td><td>0.61(0.48-0.77)</td><td>0.91</td><td>0.46</td><td>0.52</td></tr><tr><td>12</td><td>rs2283275</td><td>2,054,821</td><td>G/A</td><td>4.362 × 10-6</td><td>0.59(0.47-0.74)</td><td>0.10</td><td>0.10</td><td>0.98</td></tr><tr><td>1... |
e6386c1644aa3c1fdb0e75624296aa796c5eddeb85fe3f548a6803754bb699a5.png | simple | <table><tr><td> </td><td>T1</td><td>T2</td><td>T3</td><td><i>P</i> for trend</td></tr><tr><td>Men (<i>n</i>)</td><td>679</td><td>659</td><td>542</td><td> </td></tr><tr><td> Age (yr)</td><td>58.1 ± 10.6</td><td>54.5 ± 10.3</td><td>51.9 ± 9.4</td><td><0.001</td></tr><tr><td> Weight (kg)</td><td>68.9 ... | <table><tr><td></td><td>T1</td><td>T2</td><td>T3</td><td>P for trend</td></tr><tr><td>Men (n)</td><td>679</td><td>659</td><td>542</td><td></td></tr><tr><td>Age (yr)</td><td>58.1 ± 10.6</td><td>54.5 ± 10.3</td><td>51.9 ± 9.4</td><td><0.001</td></tr></table> | <table><tr><td>Weight (kg)</td><td>68.9 ± 10.7</td><td>74.5 ± 11.0</td><td>80.0 ± 11.8</td><td><0.001</td></tr><tr><td>BMI (kg/m2)</td><td>26.5 ± 3.9</td><td>26.2 ± 3.9</td><td>26.0 ± 3.8</td><td>0.048</td></tr><tr><td>Abdominal obesity (%)</td><td>55.2</td><td>62.2</td><td>66.2</td><td><0.001</td></tr><tr><td>Hypercho... |
66f2453f01b391cc55c43f3439d8b4518f3b67d9c547360bd1f63d97d91ad752.png | complex | <table><tr><td>Polysaccharide(s)</td><td>Source(s)</td><td>Animals</td><td>Dose/day</td><td>Duration</td><td>CNS tests performed</td><td>Significant effects</td><td>Reference</td></tr><tr><td rowspan="2">Alpha-glucan (isolichenan)</td><td rowspan="2"><i>Cetrariella islandica</i></td><td>5-week-old ♂ Std-ddY mice ... | <table><tr><td>Polysaccharide(s)</td></tr><tr><td rowspan="2">Alpha-glucan (isolichenan)</td></tr><tr></tr><tr><td>Arabinoxylan; beta-glucan</td></tr><tr><td>Pectin</td></tr><tr><td>Polysaccharide fraction: PSF (no characterization provided)</td></tr><tr><td>Alpha-glucan (FPS)</td></tr></table> | <table><tr><td>Source(s)</td><td>Animals</td><td>Dose/day</td><td>Duration</td><td>CNS tests performed</td><td>Significant effects</td><td>Reference</td></tr><tr><td rowspan="2">Cetrariella islandica</td><td>5-week-old ♂ Std-ddY mice treated with 30% ethanol p.o. 20 minutes before learning trial</td><td>100, 200, or 40... |
d592b6d2899c34ad1c98833a0c1da8b57f8fbdc25558bfe903b7f09eeab19a79.png | complex | <table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td><td><i>P</i><sub>trend</sub></td></tr><tr><td colspan="6">TyG</td></tr><tr><td> Range</td><td><8.16</td><td>8.16 to 8.47</td><td>8.48 to 8.81</td><td>≥8.82</td><td></td></tr><tr><td> No. of cases</td><td>18</td><td>... | <table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td><td>Ptrend</td></tr><tr><td colspan="6">TyG</td></tr><tr><td>Range</td><td><8.16</td><td>8.16 to 8.47</td><td>8.48 to 8.81</td><td>≥8.82</td><td></td></tr><tr><td>No. of cases</td><td>18</td><td>35</td><td>52</td><td>88</td>... | <table><tr><td></td><td>Quartile 1</td><td>Quartile 2</td><td>Quartile 3</td><td>Quartile 4</td><td>Ptrend</td></tr><tr><td>Unadjusted model</td><td>1 (ref)</td><td>0.95 (0.58–1.55)</td><td>1.15 (0.68–1.93)</td><td>2.19 (1.41–3.39)</td><td><0.001</td></tr><tr><td>Multivariable adjusted model 1b</td><td>1 (ref)</td><td>... |
1c161a4d6cb685a7a1bfd07901c96fd8b16410608cca946c49b17c11ad065c39.png | simple | <table><tr><td>Characteristic</td><td>HES APC<sup>a</sup></td><td>England<sup>b</sup></td></tr><tr><td>Finished consultant episodes</td><td>18731964</td><td></td></tr><tr><td>Admissions</td><td>15892434</td><td></td></tr><tr><td>Admission type</td><td></td><td></td></tr><tr><td> Emergency</td><td>5615707 (30.0)</td><td... | <table><tr><td>Characteristic</td><td>HES APCa</td><td>Englandb</td></tr><tr><td>Finished consultant episodes</td><td>18731964</td><td></td></tr><tr><td>Admissions</td><td>15892434</td><td></td></tr><tr><td>Admission type</td><td></td><td></td></tr><tr><td>Emergency</td><td>5615707 (30.0)</td><td></td></tr><tr><td>Wait... | <table><tr><td>Characteristic</td><td>HES APCa</td><td>Englandb</td></tr><tr><td>Planned</td><td>2154564 (11.5)</td><td></td></tr><tr><td>Other</td><td>2002929 (10.7)</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td>Male</td><td>8359362 (44.6)</td><td>26773200 (49.3)</td></tr><tr><td>Female</td><td>1037... |
18a0c09bda3cc11f6eaacc096471a8ed105b481aef3d5fcb7986b2327da527a9.png | complex | <table><tr><td>miRNAs</td><td>Expression in lung cancer</td><td>Cellular processes affected and targets</td><td>Reference</td></tr><tr><td rowspan="3">Let-7 family</td><td rowspan="3">Decreased</td><td>(i) Cell proliferation (KRAS, MYC, and HMGA2)</td><td>[28–30]</td></tr><tr><td>(ii) miRNA maturation Dicer media... | <table><tr><td>miRN</td><td>Expression in lun</td><td>Cellular processes affe</td><td>Refe</td></tr></table> | <table><tr><td>As</td><td>g cancer</td><td>cted and targets</td><td>rence</td></tr><tr><td rowspan="3">Let-7 family</td><td rowspan="3">Decreased</td><td>(i) Cell proliferation (KRAS, MYC, and HMGA2)</td><td>[28–30]</td></tr><tr><td>(ii) miRNA maturation Dicer mediated</td><td>[31]</td></tr><tr><td>(iii) Cell-cycle reg... |
f6b497bcdffbd4a90b146b1b041d931afb38b61e7470ad6e282c9513b11d257b.png | complex | <table><tr><td> </td><td colspan="3">SL2 clinical data</td><td>SL1 clinical data</td><td>p-value</td></tr><tr><td> </td><td>Pre 24 hour</td><td>Pilot trial (+)</td><td>Post 24 hour</td><td>Pilot trial (+)</td><td>SL1 vs. SL2</td></tr><tr><td>Number of patients:</td><td>9</td><td>9</td><td>9</td><td>9</td><td>/</td></tr... | <table><tr><td></td><td colspan="3">SL2 clinical data</td><td>SL1 clinical data</td><td>p-value</td></tr><tr><td></td><td>Pre 24 hour</td><td>Pilot trial (+)</td><td>Post 24 hour</td><td>Pilot trial (+)</td><td>SL1 vs. SL2</td></tr><tr><td>Number of patients:</td><td>9</td><td>9</td><td>9</td><td>9</td><td>/</td></tr><... | <table><tr><td></td><td colspan="3">SL2 clinical data</td><td>SL1 clinical data</td><td>p-value</td></tr><tr><td></td><td>Pre 24 hour</td><td>Pilot trial (+)</td><td>Post 24 hour</td><td>Pilot trial (+)</td><td>SL1 vs. SL2</td></tr><tr><td>% BG within 100–140 mg/dL</td><td>10.9</td><td>54.9</td><td>43.18</td><td>50.7</... |
766345879b0508585a93b51460f720a59c9ac18718f23bd5ae379f69c7c5763a.png | simple | <table><tr><td>Fatty acid</td><td>Name</td><td>Percentage in EVOO</td><td>mg FAME/g sample</td></tr><tr><td>C16:0</td><td>Palmitic acid</td><td>11,27</td><td>125,41</td></tr><tr><td>C16:1n7</td><td>Palmitoleic acid</td><td>0,86</td><td>9,56</td></tr><tr><td>C17:0</td><td>Margaric acid</td><td>0,04</td><td>0,46</td></tr... | <table><tr><td>Fatty acid</td><td>Name</td></tr><tr><td>C16:0</td><td>Palmitic acid</td></tr><tr><td>C16:1n7</td><td>Palmitoleic acid</td></tr><tr><td>C17:0</td><td>Margaric acid</td></tr><tr><td>C18:0</td><td>Stearic acid</td></tr><tr><td>C18:1n7c</td><td>Cis-Vaccenic acid</td></tr><tr><td>C18:1n9c</td><td>Oleic acid<... | <table><tr><td>Percentage in EVOO</td><td>mg FAME/g sample</td></tr><tr><td>11,27</td><td>125,41</td></tr><tr><td>0,86</td><td>9,56</td></tr><tr><td>0,04</td><td>0,46</td></tr><tr><td>3,85</td><td>42,81</td></tr><tr><td>2,42</td><td>26,92</td></tr><tr><td>75,99</td><td>845,97</td></tr><tr><td>4,2</td><td>46,74</td></tr... |
f5c89fa9ee87ed6e1c5341c6fb8431c1e9b10966a58e580825ab6ef69bafa2a2.png | simple | <table><tr><td>Covariate</td><td>χ<sup>2</sup></td><td>P-value</td><td>Hazard ratio</td><td>95% CI</td></tr><tr><td>Adjacent involvement (with vs. without)</td><td>11.841</td><td>0.001</td><td>2.295</td><td>1.430-3.683</td></tr><tr><td>Mitotic rate (> = 5/50 HPF vs. <5/50 HPF)</td><td>8.895</td><td>0.003</td... | <table><tr><td>Covariate</td><td>χ2</td><td>P-value</td><td>Hazard ratio</td><td>95% CI</td></tr><tr><td>Adjacent involvement (with vs. without)</td><td>11.841</td><td>0.001</td><td>2.295</td><td>1.430-3.683</td></tr><tr><td></td><td>8.89</td><td>0</td><td>2.40</td><td>1</td></tr></table> | <table><tr><td>Mitotic rate (> = 5/50 HPF vs. <5/50 HPF)</td><td>5</td><td>.003</td><td>6</td><td>.351-4.284</td></tr><tr><td>Risk grade (high risk vs. non-high risk)</td><td>26.129</td><td><0.001</td><td>11.794</td><td>4.579-30.379</td></tr></table> |
43b89362bb43a1212c966fb255d8031ebe52ba5096ff6e5e18110555db468bd7.png | complex | <table><tr><td rowspan="2">Assessment</td><td rowspan="2">Group</td><td colspan="2">Mean value (95% confidence interval)</td><td>Paired t test</td><td>1-way ANCOVA</td></tr><tr><td>PRE</td><td>POST</td><td>P (Cohen’s d)</td><td>P (Partial η2)</td></tr><tr><td rowspan="2">FMA<sub>full score</sub></td><td>Clin... | <table><tr><td rowspan="2">Assessment</td><td rowspan="2">Group</td><td colspan="2">Mean value (95% confidence interval)</td><td>Paired t test</td><td>1-way ANCOVA</td></tr><tr><td>PRE</td><td>POST</td><td>P (Cohen’s d)</td><td>P (Partial η2)</td></tr><tr><td rowspan="2">FMAfull score</td><td>Clinic</td><td>13.75 (8.09... | <table><tr><td rowspan="2">MASElbow</td><td>Clinic</td><td>1.91 (1.54–2.28)</td><td>1.18 (0.82–1.53)</td><td>0.001 (1.08)***</td><td rowspan="2">0.892 (0.001)</td></tr><tr><td>Lab</td><td>1.21 (0.77–1.66)</td><td>0.76 (0.40–1.12)</td><td>0.013 (0.71)*</td></tr></table> |
02a0d2e18f63a62a68e36747766f8a3a3a588b23e55a3df37170224a176f3cf7.png | complex | <table><tr><td> </td><td colspan="2">Validation against our test</td><td colspan="2">Validation against the test in literature</td></tr><tr><td> </td><td>The current experiment (n = 8)</td><td>Predicted value</td><td>Hashemi et al.’s experiment (n > 4)</td><td>Predicted value</td></tr><tr><td>High density</td>... | <table><tr><td></td><td colspan="2">Validation against our test</td><td>Validation against the test in literature</td></tr><tr><td></td><td>The current experiment (n = 8)</td><td>Predicted value</td><td>Hashemi et al.’s experiment (n > 4)</td></tr><tr><td>High density</td><td>2015 ± 95.7 N</td><td>2028.8 N</td><td>2132... | <table><tr><td>Validation against the test in literature</td></tr><tr><td>Predicted value</td></tr><tr><td>2028.8 N</td></tr><tr><td>607 N</td></tr></table> |
82e0a1442e400a6f6a93cb3aea64a984eb88dbe1e6ee51d0201c8383317325bf.png | simple | <table><tr><td></td><td>n</td><td>%</td></tr><tr><td><i>Gender</i></td><td></td><td></td></tr><tr><td> Male</td><td>432</td><td>49.3</td></tr><tr><td> Female</td><td>444</td><td>50.7</td></tr><tr><td><i>Ethnicity</i></td><td></td><td></td></tr><tr><td> White</td><td>536</td><td>61.2</td></tr><tr><td> Non-white</td><td>... | <table><tr><td></td><td>n</td><td>%</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Male</td><td>432</td><td>49.3</td></tr><tr><td>Female</td><td>444</td><td>50.7</td></tr><tr><td>Ethnicity</td><td></td><td></td></tr><tr><td>White</td><td>536</td><td>61.2</td></tr><tr><td>Non-white</td><td>340</td><td>38.8</... | <table><tr><td>Atypical Medication</td><td></td><td></td></tr><tr><td>On a atypical medication</td><td>628</td><td>71.7</td></tr><tr><td></td><td>Mean</td><td>SD</td></tr><tr><td>Age</td><td>43.03</td><td>11.80</td></tr><tr><td>Number of comorbidities</td><td>1.27</td><td>1.30</td></tr></table> |
03305186bf6e520f92ba4af80eef1384d53b5a71565844067af6a2b2426fb2b1.png | simple | <table><tr><td>Variable</td><td>ROSC</td><td>No ROSC</td><td>P value</td></tr><tr><td>Paramedics with prior OHCA case volume ≥ 15 (%)</td><td>24.5</td><td>22.7</td><td><0.01</td></tr><tr><td>Male gender (%)</td><td>60.1</td><td>63.2</td><td>0.01</td></tr><tr><td>Non-Caucasian (%)</td><td>31.7</td><td>29.8</td>... | <table><tr><td>Variable</td></tr><tr><td>Paramedics with prior OHCA case volume ≥ 15 (%)</td></tr><tr><td>Male gender (%)</td></tr><tr><td>Non-Caucasian (%)</td></tr><tr><td>Age in years (mean, ± SD)</td></tr><tr><td>Shockable rhythm (%)</td></tr><tr><td>Layperson/first responder CPR (%)</td></tr><tr><td>EMS response t... | <table><tr><td>ROSC</td><td>No ROSC</td><td>P value</td></tr><tr><td>24.5</td><td>22.7</td><td><0.01</td></tr><tr><td>60.1</td><td>63.2</td><td>0.01</td></tr><tr><td>31.7</td><td>29.8</td><td>0.09</td></tr><tr><td>65.7</td><td>67.4</td><td><0.01</td></tr><tr><td>38.9</td><td>21.2</td><td><0.01</td></tr><tr><td>51.8</td... |
f3d6dc897b4090bacc78575c48fa0296ea4edf84de7e36e54a454d0d77ae4642.png | simple | <table><tr><td>Component</td><td>Score</td><td>Definition</td></tr><tr><td>Physical Activity</td><td></td><td></td></tr><tr><td></td><td>0</td><td>No exercise</td></tr><tr><td></td><td>1</td><td>1–149 min of moderate exercise or 1–74 min of vigorous exercise/week</td></tr><tr><td></td><td>2</td><td>150+ min... | <table><tr><td>Component</td><td>Score</td><td>Definition</td></tr><tr><td>Physical Activity</td><td></td><td></td></tr><tr><td></td><td>0</td><td>No exercise</td></tr><tr><td></td><td>1</td><td>1–149 min of moderate exercise or 1–74 min of vigorous exercise/week</td></tr><tr><td></td><td>2</td><td>150+ minutes of mode... | <table><tr><td>Component</td><td>Score</td><td>Definition</td></tr><tr><td></td><td>0</td><td>≥30 kg/m2</td></tr><tr><td></td><td>1</td><td>25.0–29.99 kg/m2</td></tr><tr><td></td><td>2</td><td><25.0 kg/m2</td></tr><tr><td>Cholesterol</td><td></td><td></td></tr><tr><td></td><td>0</td><td>≥240 mg/dL</td></tr><tr><td></td... |
1d4b19eebc8b6a5e56722c8fff8ac365c32c9b934524ea0fb40dbd26ad53378d.png | simple | <table><tr><td>Cancer type</td><td>Reference</td></tr><tr><td>Breast</td><td>Fernandez et al. (19), Gazit et al. (20)</td></tr><tr><td>Prostate</td><td>Daneshmand et al. (23), Fu et al. (24)</td></tr><tr><td>Gastric</td><td>Song et al. (26)</td></tr><tr><td>Ovarian</td><td>Huang, LW et al. (25)</td></tr><tr><td>Endomet... | <table><tr><td>Cancer type</td><td>Reference</td></tr><tr><td>Breast</td><td>Fernandez et al. (19), Gazit et al. (20)</td></tr><tr><td>Prostate</td><td>Daneshmand et al. (23), Fu et al. (24)</td></tr><tr><td>Gastric</td><td>Song et al. (26)</td></tr><tr><td>Ovarian</td><td>Huang, LW et al. (25)</td></tr><tr><td>Endomet... | <table><tr><td>Cancer type</td><td>Reference</td></tr><tr><td>Fibrosarcoma</td><td>Jamora et al. (35)</td></tr><tr><td>Glioma</td><td>Pyrko et al. (34)</td></tr><tr><td>Melanoma</td><td>Zhuang et al. (33)</td></tr><tr><td>Lung</td><td>Lin et al. (21), Koomagi et al. (22)</td></tr><tr><td>Renal</td><td>Fu et al. (30)</t... |
1cc55ecb5c31afc3cf1faddd8d26d60293fa8f811141b488f1bfa172b4fe1c0f.png | complex | <table><tr><td>LN</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td colspan="2">CD63</td><td> </td></tr><tr><td> </td><td> </td><td>Number of patients, <i>n </i>(%)</td><td>Positive, <i>n</i></td><td>Negative, <i>n</i></td><td>P-value</td></tr><tr><td>MDR1</td><td>Positive... | <table><tr><td>LN</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">CD63</td><td></td></tr><tr><td></td><td></td><td>Number of patients, n (%)</td><td>Positive, n</td><td>Negative, n</td><td>P-value</td></tr></table> | <table><tr><td>MDR1</td><td>Positive</td><td>11 (22.9)</td><td>11</td><td>0</td><td></td></tr><tr><td></td><td>Negative</td><td>37 (77.1)</td><td>16</td><td>21</td><td>P < 0.05</td></tr></table> |
4a51aa875303d7dd772fae2f8c792a01127204a2d1efa0fcb9880015b1b0ef70.png | complex | <table><tr><td rowspan="2">Capsules</td><td colspan="3">Spectrophotometric method</td><td colspan="3">Fluorimetric method</td></tr><tr><td>Recovery (%) ± SD<sup>(a)</sup></td><td><i>F </i> value<sup>(b)</sup></td><td><i>t </i> value<sup>(b)</sup></td><td>Recovery (%) ± SD<sup>(a)</sup></td><td><i>F </i> value... | <table><tr><td rowspan="2">Capsules</td><td colspan="3">Spectrophotometric method</td><td colspan="3">Fluorimetric method</td></tr><tr><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td></tr><tr><td>Prozac</td><td>99.9 ± 1.4</td><td>... | <table><tr><td rowspan="2">Capsules</td><td colspan="3">Spectrophotometric method</td><td colspan="3">Fluorimetric method</td></tr><tr><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td><td>Recovery (%) ± SD(a)</td><td>F value(b)</td><td>t value(b)</td></tr><tr><td>lipax</td><td>.3</td><td>.00</td><... |
f93f11c178fd2f256b7976590aa708fe0443803e1b48fb408f1851c4fc0c4681.png | simple | <table><tr><td></td><td>Age (Years)</td><td>Height (cm)</td><td>Weight (kg)</td></tr><tr><td>CFS</td><td>43 ± 4.6</td><td>164 ± 7.3</td><td>73 ± 21.2</td></tr><tr><td>Control</td><td>43 ± 6.5</td><td>167 ± 7.0</td><td>70 ± 16.7</td></tr></table> | <table><tr><td></td><td>Age (Years)</td><td>Height (cm)</td><td>Weight (kg)</td></tr></table> | <table><tr><td>CFS</td><td>43 ± 4.6</td><td>164 ± 7.3</td><td>73 ± 21.2</td></tr><tr><td>Control</td><td>43 ± 6.5</td><td>167 ± 7.0</td><td>70 ± 16.7</td></tr></table> |
c196951cfb266d3655e64d237ae509e40f09f13b9d0c046379bc0e56be472526.png | complex | <table><tr><td></td><td>General health</td><td>Conditions and symptoms</td><td>Infections</td></tr><tr><td colspan="4">‘Type 1’</td></tr><tr><td> 1a: Emerging female excess</td><td>General health – Past year General health – Past month</td><td>High temperature Rash</td><td>Eye infection Ear infe... | <table><tr><td></td><td>General health</td><td>Conditions and symptoms</td><td>Infections</td></tr><tr><td colspan="4">‘Type 1’</td></tr><tr><td>1a: Emerging female excess</td><td>General health – Past year General health – Past month</td><td>High temperature Rash</td><td>Eye infection Ear infection</td></tr><tr><td>1b... | <table><tr><td></td><td>General health</td><td>Conditions and symptoms</td><td>Infections</td></tr><tr><td>2c: Consistent male excess</td><td></td><td>Wheezing Asthma Hay fever</td><td>Chest infection</td></tr><tr><td colspan="4">‘Type 3’</td></tr><tr><td>3a: Emerging male excess</td><td></td><td>Pain in arms/legs</td>... |
77d3c275275aaebf41c31adfe7c1328f167546d357ec89bf01a45ff6c833d196.png | simple | <table><tr><td>Sample</td><td>ZKR <sup>a</sup>_S1 <sup>b</sup></td><td>ZKR_S2 <sup>b</sup></td><td>ZKR_S3 <sup>b</sup></td><td>QXR <sup>c</sup>_S1</td><td>QXR_S2</td><td>QXR_S3</td></tr><tr><td>Raw reads</td><td>100,481,781</td><td>99,812,614</td><td>99,445,825</td><td>100,002,793</td><td>99,887,525</td><td>99,071,615<... | <table><tr><td>Sample</td><td>ZKR a_S1 b</td><td>ZKR_S2 b</td><td>ZKR_S3 b</td><td>QXR c_S1</td><td>QXR_S2</td><td>QXR_S3</td></tr><tr><td>Raw reads</td><td>100,481,781</td><td>99,812,614</td><td>99,445,825</td><td>100,002,793</td><td>99,887,525</td><td>99,071,615</td></tr></table> | <table><tr><td>Sample</td><td>ZKR a_S1 b</td><td>ZKR_S2 b</td><td>ZKR_S3 b</td><td>QXR c_S1</td><td>QXR_S2</td><td>QXR_S3</td></tr><tr><td>Clean reads</td><td>95,660,601</td><td>94,297,177</td><td>90,539,959</td><td>97,386,913</td><td>97,460,159</td><td>91,414,542</td></tr><tr><td>Filtering rate</td><td>93.26%</td><td>... |
6665a0f982c5ff2c085761ab7d163538d7cbcf6905b116335f67b2fb06e2359c.png | simple | <table><tr><td>Cross-linked polyurethane</td><td>Macrodiols</td><td>Diisocyanate</td><td>Chain extender</td><td>State at room temperature</td><td>T<sub>g</sub> (°C)</td><td><i>T</i><sub><i>m</i></sub> (°C)</td></tr><tr><td>CPU 1</td><td>PCEG 1</td><td>HDI</td><td>TMP</td><td>Hard</td><td>−45</td><td>46<... | <table><tr><td>Cross-linked polyurethane</td><td>Macrodiols</td><td>Diisocyanate</td><td>Chain extender</td><td>State at room temperature</td></tr><tr><td>CPU 1</td><td>PCEG 1</td><td>HDI</td><td>TMP</td><td>Hard</td></tr><tr><td>CPU 2</td><td>PCEG 2</td><td>HDI</td><td>TMP</td><td>Frangibility</td></tr><tr><td>CPU 3</... | <table><tr><td>Tg (°C)</td><td>Tm (°C)</td></tr><tr><td>−45</td><td>46</td></tr><tr><td>−48</td><td>44</td></tr><tr><td>−51</td><td>38</td></tr></table> |
1e1bf45acf4127fec4c2715a7a3ab139b4533f2c18f001ba374498778fab92ed.png | simple | <table><tr><td>Striatal Region<sup>ψ</sup></td><td>PD (n = 65)</td><td>Healthy Controls (n = 27)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.416% (0.400 – 0.433)</td><td>0.468% (0.443 – 0.493)</td><td>11.38</td><td>0.001</td><td>−0.80</td></tr><tr><... | <table><tr><td>Striatal Regionψ</td><td>PD (n = 65)</td><td>Healthy Controls (n = 27)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Caudate</td><td>0.416% (0.400 – 0.433)</td><td>0.468% (0.443 – 0.493)</td><td>11.38</td><td>0.001</td><td>−0.80</td></tr><tr><td>Normalized Putamen</td><td>0.42... | <table><tr><td>Striatal Regionψ</td><td>PD (n = 65)</td><td>Healthy Controls (n = 27)</td><td>F(1,91)</td><td>p</td><td>Effect size</td></tr><tr><td>Normalized Body</td><td>0.071% (0.064 – 0.077)</td><td>0.078% (0.070 – 0.086)</td><td>2.0</td><td>0.16</td><td>−0.32</td></tr><tr><td>Cognitively normal comparison*</td><t... |
6e035626f5a47ae6f104402e41d320be8429886195e981df220695af37107f1e.png | complex | <table><tr><td></td><td colspan="4">Aerobe genomes</td><td colspan="4">Anaerobe genomes</td><td colspan="4">Facultative genomes</td></tr><tr><td rowspan="3">Predictions</td><td>Aerobe</td><td>137</td><td>87</td><td>%</td><td>Aerobe</td><td>6</td><td>6</td><td>%</td><td>Aerobe</td><td>43</td><td>44</td><td>%</td></tr><t... | <table><tr><td></td></tr><tr><td rowspan="3">Predictions</td></tr><tr></tr><tr></tr></table> | <table><tr><td colspan="4">Aerobe genomes</td><td colspan="4">Anaerobe genomes</td><td colspan="4">Facultative genomes</td></tr><tr><td>Aerobe</td><td>137</td><td>87</td><td>%</td><td>Aerobe</td><td>6</td><td>6</td><td>%</td><td>Aerobe</td><td>43</td><td>44</td><td>%</td></tr><tr><td>Anaerobe</td><td>3</td><td>2</td><t... |
cf56af6e2298c40519a3b8aad02e71641bb5cf99809cb5ccf344ae094f6c563e.png | complex | <table><tr><td colspan="3">Male to female ratio is 432(73%): 160(27%)</td></tr><tr><td>Characteristics</td><td>Cases (n = 296)</td><td>Controls (n = 296)</td></tr><tr><td></td><td>n* (%)</td><td>n* (%)</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td>- Married</td><td>227 (76.69%)</td><td>251 (84.80%)... | <table><tr><td colspan="3">Male to female ratio is 432(73%): 160(27%)</td></tr><tr><td>Characteristics</td><td>Cases (n = 296)</td><td>Controls (n = 296)</td></tr></table> | <table><tr><td colspan="3">Male to female ratio is 432(73%): 160(27%)</td></tr><tr><td></td><td>n* (%)</td><td>n* (%)</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td>- Married</td><td>227 (76.69%)</td><td>251 (84.80%)</td></tr><tr><td>Family type</td><td></td><td></td></tr><tr><td>- Nuclear family</t... |
f9b0ce1a3f23941778e9cc1a8bd85d0a0ffb7ec75c1ccd297044c0c4816d9515.png | simple | <table><tr><td>Annotation type</td><td>Content</td><td>Elements involved</td></tr><tr><td>Curatorial</td><td>Meta annotation referring annotations commented on by a curator. Each annotated value can be accepted, rejected and discussed</td><td>All elements of the curated annotation</td></tr><tr><td>Batch</td><td>Meta an... | <table><tr><td>Annotation type</td><td>Content</td><td>Elements involved</td></tr></table> | <table><tr><td>Curatorial</td><td>Meta annotation referring annotations commented on by a curator. Each annotated value can be accepted, rejected and discussed</td><td>All elements of the curated annotation</td></tr><tr><td>Batch</td><td>Meta annotation linking identical annotations referring to different annotated rec... |
2b1a745200d190df21a1016c35a1d76eae98b44e46693ab4858b5681af51e1a6.png | simple | <table><tr><td>Outcome</td><td>Persons with symptomatic RHOA (<i>n</i> = 718), mean (s.d.)</td><td>Persons with EOA (<i>n</i> = 80), mean (s.d.)</td><td>Adjusted mean difference<sup>a</sup> (95% CI)</td></tr><tr><td>Female, <i>n</i> (%)</td><td>442 (62)</td><td>67 (84)</td><td>22.2 (13.4, 31.0)</td></tr><tr><td>Age, ye... | <table><tr><td>Outcome</td><td>Persons with symptomatic RHOA (n = 718), mean (s.d.)</td></tr><tr><td>Female, n (%)</td><td>442 (62)</td></tr><tr><td>Age, years</td><td>66.1 (8.1)</td></tr><tr><td>BMI, kg/m2</td><td>29.3 (5.1)</td></tr><tr><td>AUSCAN pain</td><td>6.6 (4.2)</td></tr><tr><td>AUSCAN stiffness</td><td>1.1 (... | <table><tr><td>Persons with EOA (n = 80), mean (s.d.)</td><td>Adjusted mean differencea (95% CI)</td></tr><tr><td>67 (84)</td><td>22.2 (13.4, 31.0)</td></tr><tr><td>69.2 (7.8)</td><td>3.1 (1.3, 5.0)</td></tr><tr><td>28.7 (5.1)</td><td>−0.6 (−1.7, 0.6)</td></tr><tr><td>8.0 (4.2)</td><td>1.3 (0.3, 2.3)</td></tr><tr><td>1... |
7850b0b1fa83529112d7eabd9cd86f04d1b95a3a2a285d6157eeda65b48973f1.png | complex | <table><tr><td rowspan="2">Eikelboom morphotype<sup>a</sup></td><td rowspan="2">Taxonomy</td><td colspan="5">Classification</td></tr><tr><td>Phylum</td><td>Class</td><td>Order</td><td>Family</td><td>Genus</td></tr><tr><td rowspan="4">0092 (30)</td><td>RDP<sup>b</sup></td><td><i>Chloroflexi</i></td><td><i>Anaerolineae</... | <table><tr><td rowspan="2">Eikelboom morphotypea</td><td rowspan="2">Taxonomy</td><td colspan="3">Classification</td></tr><tr><td>Phylum</td><td>Class</td><td>Order</td></tr><tr><td rowspan="4">0092 (30)</td><td>RDPb</td><td>Chloroflexi</td><td>Anaerolineae</td><td>Anaerolineales</td></tr><tr><td>Greengenesc</td><td>Ch... | <table><tr><td colspan="2">Classification</td></tr><tr><td>Family</td><td>Genus</td></tr><tr><td>Anaerolineaceae</td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>2-1</td><td>B45</td></tr><tr><td>Caldilineaceae</td><td>Caldilinea</td></tr><tr><td>Caldilineaceae</td><td>Caldilinea</td></tr>... |
988f48ec6a8f2b5e942d940a233944d094ce872c4535b64cc80d855b20e8af21.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="3">Codes</td></tr><tr><td>−1</td><td>0</td><td>+1</td></tr><tr><td>Frying temperature (<sup>°</sup>C)</td><td>140</td><td>150</td><td>160</td></tr><tr><td>Frying time (min)</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Level of BSCF (%)</td><td>20</td><t... | <table><tr><td rowspan="2">Variables</td><td>Codes</td></tr><tr><td>−1</td></tr><tr><td>Frying temperature (°C)</td><td>140</td></tr><tr><td>Frying time (min)</td><td>2</td></tr><tr><td>Level of BSCF (%)</td><td>20</td></tr><tr><td>Thickness (mm)</td><td>2</td></tr></table> | <table><tr><td colspan="2">Codes</td></tr><tr><td>0</td><td>+1</td></tr><tr><td>150</td><td>160</td></tr><tr><td>3</td><td>4</td></tr><tr><td>30</td><td>40</td></tr><tr><td>3</td><td>4</td></tr></table> |
f2f56fe2f4e1d83525dd921516d6e4c78845b885f3b1065923b9c4522a97de87.png | simple | <table><tr><td>Material</td><td>Element type</td><td>Constitutive relation</td><td>Material properties</td></tr><tr><td>Bony structures</td><td></td><td></td><td></td></tr><tr><td>Vertebral cortical bone, endplates, and posterior cortical bone</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td><i>E... | <table><tr><td>Material</td><td>Element type</td><td>Constitutive relation</td><td>Material properties</td></tr><tr><td>Bony structures</td><td></td><td></td><td></td></tr><tr><td>Vertebral cortical bone, endplates, and posterior cortical bone</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td>E = ... | <table><tr><td>Intervertebral disk</td><td></td><td></td><td></td></tr><tr><td>Nucleus pulposus</td><td>8 Nodes brick element (C3D8)</td><td>Isotropic, elastic</td><td>E = 2 MPa ν = 0.499</td></tr><tr><td>Annulus fibrosus</td><td>8 Nodes brick element (C3D8)</td><td>Hyperelastic anisotropic (HGO)</td><td>Table 2</td></... |
e1c384ef4948a16d4e6c1305ffb1b27556cf160551dd5dc8c81bcdd02873d841.png | complex | <table><tr><td></td><td colspan="6">Men</td><td colspan="8">Women</td></tr><tr><td></td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 3b</td></tr><tr><td></td><td>OR</td><td></... | <table><tr><td></td><td colspan="6">Men</td><td colspan="8">Women</td></tr><tr><td></td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 0</td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 3b</td></tr><tr><td></td><td>OR</td><td></... | <table><tr><td>Illiterate, no diploma, or primary education</td><td></td><td></td><td>1.41</td><td>***</td><td>1.40</td><td>***</td><td></td><td></td><td>1.67</td><td>***</td><td>1.70</td><td>***</td><td>1.71</td><td>***</td></tr><tr><td>Lower Secondary</td><td></td><td></td><td>1.21</td><td>**</td><td>1.20</td><td>**<... |
cdf6bb3fba2f442abd2d00d2939009991eeb2a10ee73d5a624cac4bb302b723b.png | complex | <table><tr><td></td><td colspan="3">Frequency</td></tr><tr><td></td><td>Current employment</td><td>Not working as nurses</td><td>Total</td></tr><tr><td>1994</td><td>18</td><td>5</td><td>23</td></tr><tr><td>1995</td><td>13</td><td>5</td><td>18</td></tr><tr><td>1996</td><td>15</td><td>6</td><td>21</td></tr><tr><td>1997</... | <table><tr><td></td></tr><tr><td></td></tr><tr><td>1994</td></tr><tr><td>1995</td></tr><tr><td>1996</td></tr><tr><td>1997</td></tr><tr><td>2001</td></tr><tr><td>2002</td></tr><tr><td>2005</td></tr><tr><td>2006</td></tr><tr><td>2007</td></tr><tr><td>2009</td></tr><tr><td>2011</td></tr><tr><td>Total</td></tr></table> | <table><tr><td colspan="3">Frequency</td></tr><tr><td>Current employment</td><td>Not working as nurses</td><td>Total</td></tr><tr><td>18</td><td>5</td><td>23</td></tr><tr><td>13</td><td>5</td><td>18</td></tr><tr><td>15</td><td>6</td><td>21</td></tr><tr><td>23</td><td>2</td><td>25</td></tr><tr><td>20</td><td>4</td><td>2... |
cc785b8e4b63f2da04ed6dd945fcb283d124876c6a3f46481f0838000a00306f.png | complex | <table><tr><td colspan="2"> </td><td>LFI strip test</td><td>DAS ELISA (OD)</td></tr><tr><td rowspan="3">Pig 77</td><td>Swap 1</td><td>+</td><td>1.717</td></tr><tr><td>Swap 2</td><td>+</td><td>1.3</td></tr><tr><td>Swap 3</td><td>+</td><td>0.307</td></tr><tr><td>Pig 78</td><td>Swap 1</td><td>+</td><td>0.604</td></tr><tr>... | <table><tr><td colspan="2"></td><td>LFI strip test</td><td>DAS ELISA (OD)</td></tr><tr><td rowspan="3">Pig 77</td><td>Swap 1</td><td>+</td><td>1.717</td></tr><tr><td>Swap 2</td><td>+</td><td>1.3</td></tr><tr><td>Swap 3</td><td>+</td><td>0.307</td></tr><tr><td>Pig 78</td><td>Swap 1</td><td>+</td><td>0.604</td></tr><tr><... | <table><tr><td rowspan="2">Pig 79</td><td>Swap 2</td><td>+</td><td>0.833</td></tr><tr><td>Swap 3</td><td>+</td><td>2.04</td></tr><tr><td rowspan="3">Pig 80</td><td>Swap 1</td><td>+</td><td>3.079</td></tr><tr><td>Swap 2</td><td>+</td><td>3.372</td></tr><tr><td>Swap 3</td><td>+</td><td>2.713</td></tr><tr><td></td><td>Swa... |
aa78872c4cd7038e9abbe4ca9c8794f460065d0b3e3c24f1225e9dfcb3a0dfe6.png | simple | <table><tr><td>Causes of pulmonary hypertension in ICU</td><td>Causes of RV failure in ICU</td></tr><tr><td>1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD)</td><td>1) RV Pressure overload, pulmonary hypertension, any cause</td></tr><tr><td>2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/c... | <table><tr><td>Causes of pulmonary hypertension in ICU</td><td>Causes of RV failure in ICU</td></tr><tr><td>1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD)</td><td>1) RV Pressure overload, pulmonary hypertension, any cause</td></tr><tr><td>2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/c... | <table><tr><td>4) Thromboembolic (for example, acute PE; chronic (CTEPH); other causes of emboli (AFE, air, cement)</td><td>3) RV-volume overload</td></tr><tr><td>5) Mechanical (for example, increased Pplat - IPPV</td><td>Cardiac causes: tricuspid and pulmonary regurgitation; intracardiac shunts</td></tr></table> |
252f68b4abf65d5b82890d0191c25cd3710fcfcb5a7232245751f5206413049a.png | complex | <table><tr><td>Gene</td><td>5′–3′ sequence</td></tr><tr><td rowspan="2"><i>P5CS1</i></td><td>F‐GTAGACGACGACGACGATAATG</td></tr><tr><td>R‐ACTGCTGTCCCAACCTTAAC</td></tr><tr><td rowspan="2"><i>P5CS2</i></td><td>F‐GGTGCTGAGGTGGGAATAAG</td></tr><tr><td>R‐ACTTGTCCCTTTCCTCTCATTATC</td... | <table><tr><td>Gene</td></tr><tr><td rowspan="2">P5CS1</td></tr><tr></tr><tr><td rowspan="2">P5CS2</td></tr><tr></tr><tr><td rowspan="2">P5CR</td></tr><tr></tr><tr><td rowspan="2">OAT</td></tr><tr></tr><tr><td rowspan="2">PDH1</td></tr><tr></tr><tr><td rowspan="2">PDH2</td></tr><tr></tr><tr><td rowspan="2">P5CDH</td></... | <table><tr><td>5′–3′ sequence</td></tr><tr><td>F‐GTAGACGACGACGACGATAATG</td></tr><tr><td>R‐ACTGCTGTCCCAACCTTAAC</td></tr><tr><td>F‐GGTGCTGAGGTGGGAATAAG</td></tr><tr><td>R‐ACTTGTCCCTTTCCTCTCATTATC</td></tr><tr><td>F‐GAGGAGTAGCTGCTGGTTTAC</td></tr><tr><td>R‐CCTGGATGCTTCCCAGTTT</td></tr><tr><td>F‐TGCTTGAGCTTGAAGGAGAG</td>... |
042e505ba6e8f03c5791843f32348c38822664c70bae401c94f3ede5f2473f9d.png | simple | <table><tr><td></td><td>First quartile</td><td>Third quartile</td></tr><tr><td>Shortwave radiation</td><td>164.97 (1.41)*</td><td>141.35(1.14)</td></tr><tr><td>HDD</td><td>134.62(1.22)</td><td>168.11(1.39)</td></tr><tr><td>Snowfall</td><td>135.04(1.24)</td><td>163.66(1.42)</td></tr><tr><td>Rainfall</td><td>164.69 (1.60... | <table><tr><td></td><td>First quartile</td><td>Third quartile</td></tr><tr><td>Shortwave radiation</td><td>164.97 (1.41)*</td><td>141.35(1.14)</td></tr><tr><td>HDD</td><td>134.62(1.22)</td><td>168.11(1.39)</td></tr><tr><td>Snowfall</td><td>135.04(1.24)</td><td>163.66(1.42)</td></tr><tr><td>Rainfall</td><td>164.69 (1.60... | <table><tr><td></td><td>)</td><td>82(1.32)</td></tr><tr><td>Permitted air emissions</td><td>142.96(1.09)</td><td>149.01(1.12)</td></tr><tr><td>Acres of land used to grow crops</td><td>142.09(1.29)</td><td>157.14(1.53)</td></tr></table> |
dfd2f0a62259c18dc1176048b31b767b26be7c4be92ee1bc7904cadc8fef3f99.png | simple | <table><tr><td>Author</td><td>Country</td><td>Year</td><td>Type of study</td><td>Patients</td><td>Control</td><td>Cut off (pmol/L)</td><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td>SEN</td><td>SPE</td></tr><tr><td>Moore RG <i>et al</i>. [5]</td><td>USA</td><td>2008</td><td>prospective/retrospective</td><td>171</td><t... | <table><tr><td>Author</td><td>Country</td><td>Year</td><td>Type of study</td><td>Patients</td><td>Control</td><td>Cut off (pmol/L)</td><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td>SEN</td><td>SPE</td></tr><tr><td>Moore RG et al. [5]</td><td>USA</td><td>2008</td><td>prospective/retrospective</td><td>171</td><td>156</... | <table><tr><td>Author</td><td>Country</td><td>Year</td><td>Type of study</td><td>Patients</td><td>Control</td><td>Cut off (pmol/L)</td><td>TP</td><td>FP</td><td>FN</td><td>TN</td><td>SEN</td><td>SPE</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>64</td><td>127</td><td>6</td><td>66</td><td>119</t... |
f17e733922aa880bbde08b831fbb173dc9da5b04e63cc94d11b485ea0a897bd9.png | simple | <table><tr><td>Training description</td><td>Related themes</td></tr><tr><td>1. Video: Invite for the workshop and foundational information on <i>Rx for Change</i> and systematic reviews<underline>Delivery:</underline> A video (prezi with audio narration) covering general information about <i>Rx for Change</i> and syste... | <table><tr><td>Training description</td><td>Related themes</td></tr><tr><td>1. Video: Invite for the workshop and foundational information on Rx for Change and systematic reviewsDelivery: A video (prezi with audio narration) covering general information about Rx for Change and systematic reviews; the video was sent ele... | <table><tr><td>3. Post-training remindersDelivery: Emailed at 1 and 3 months post-workshopContent: Cues and/or reminders regarding the database’s use, value, updates, and navigation tips</td><td>Routine habits</td></tr></table> |
ebafea3f86882c03d4a523702e9b74832a556fc0bab58ed0919c1a8691b6e81c.png | simple | <table><tr><td>Motif</td><td>Number of matches</td></tr><tr><td><i>P. pastoris</i> AT-ACS</td><td>15</td></tr><tr><td><i>P. pastoris</i> GC-ACS</td><td>1</td></tr><tr><td><i>S. cerevisiae</i> 11 bp ACS</td><td>11</td></tr><tr><td><i>S. cerevisiae</i> 17 bp ACS</td><td>6</td></tr></table> | <table><tr><td>Motif</td><td>Number of matches</td></tr><tr><td>P. pastoris AT-ACS</td><td>15</td></tr><tr><td>P. pastoris GC-ACS</td><td>1</td></tr><tr><td>S. cerevisiae 11 bp ACS</td><td>11</td></tr></table> | <table><tr><td>Motif</td><td>Number of matches</td></tr><tr><td>S. cerevisiae 17 bp ACS</td><td>6</td></tr></table> |
ab9282df63ff6f01700ce866b137e0b29fb790f81692eb9c7db23401b9fa5b5f.png | complex | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">Overall</td><td colspan="2">AKI</td><td colspan="2">No AKI</td></tr><tr><td>N</td><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>N</td><td>14,651</td><td></td><td>1966</td><td>(13.4% of cohort)</td><td>12,685</td><td>(86.6% of cohort)</td></t... | <table><tr><td rowspan="2">Characteristic</td><td>Overall</td></tr><tr><td>N</td></tr><tr><td>N</td><td>14,651</td></tr><tr><td>Age in years (median & IQR)</td><td>69</td></tr><tr><td>Female</td><td>8317</td></tr><tr><td>Residential care</td><td>433</td></tr><tr><td>Deprived home locationa</td><td>1215</td></tr><tr><td... | <table><tr><td>Overall</td><td colspan="2">AKI</td><td colspan="2">No AKI</td></tr><tr><td>%</td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td></td><td>1966</td><td>(13.4% of cohort)</td><td>12,685</td><td>(86.6% of cohort)</td></tr><tr><td>(54–78)</td><td>73</td><td>(63–81)</td><td>68</td><td>(53–78)</td></tr><... |
f9ab75b18ee973ac4094971069c6d3244dae3ea43401fac83009ce0ec13b234e.png | complex | <table><tr><td>Variables</td><td>Total cohort</td><td>Tsunami group</td><td>Radiation group</td><td>p value<sup>a</sup></td></tr><tr><td>Physical examination</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Body weight (kg)</td><td>58.5 (52.0–66.0)</td><td>57.9 (52.6–65.9)</td><td>59.5 (51.9–6... | <table><tr><td>Variables</td><td>Total cohort</td><td>Tsunami group</td><td>Radiation group</td></tr><tr><td>Physical examination</td><td></td><td></td><td></td></tr><tr><td>Body weight (kg)</td><td>58.5 (52.0–66.0)</td><td>57.9 (52.6–65.9)</td><td>59.5 (51.9–66.3)</td></tr><tr><td>BMI (kg/m2)</td><td>24.2 (22.4–26.1)<... | <table><tr><td>p valuea</td></tr><tr><td></td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>0.002</td></tr><tr><td>n.s.</td></tr><tr><td></td></tr><tr><td>n.s.</td></tr><tr><td>n.s.</td></tr><tr><td>... |
dc3be347dbe2e3686f145b59300266612222e681157682f51c67596b34c00e14.png | complex | <table><tr><td>Chromosomal arm</td><td>Total no. informative SNPs with LOH</td><td>No. informative SNPs with LOH and CN = 1 (fraction)</td><td>No. informative SNPs with LOH and CN = 2 (fraction)</td><td>No. informative SNPs with LOH and CN = 3 or 4 (fraction)</td></tr><tr><td>1p</td><td>10,576</td><td>2,930 (0.28)</td>... | <table><tr><td>Chromosomal arm</td><td>Total no. informative SNPs with LOH</td><td>No. informative SNPs with LOH and CN = 1 (fraction)</td><td>No. informative SNPs with LOH and CN = 2 (fraction)</td><td>No. informative SNPs with LOH and CN = 3 or 4 (fraction)</td></tr><tr><td>1p</td><td>10,576</td><td>2,930 (0.28)</td>... | <table><tr><td>4p</td><td>12,223</td><td>4,771 (0.39)</td><td>7,452 (0.61)</td><td>0 (0)</td></tr><tr><td>4q</td><td>28,105</td><td>9,142 (0.33)</td><td>17,905 (0.64)</td><td>1,958 (0.04)</td></tr><tr><td>5p</td><td>1,315</td><td>0 (0)</td><td>1,259 (0.96)</td><td>56 (0.04)</td></tr><tr><td>5q</td><td>16,537</td><td>7,... |
6a35034fd9bbab8693d4652b1c24b6602ea4a36e3440c927ae47068adaaf01f7.png | simple | <table><tr><td>Driers</td><td>Appearance</td><td>Odor</td><td>Taste</td><td>Flavor</td><td>Texture</td><td>Palability</td><td>Acceptability</td><td>Shelf-life (1–30 days)</td></tr><tr><td>Plastic</td><td>Attractive</td><td>Pleasant</td><td>Fair</td><td>Fair</td><td>Hard</td><td>Good</td><td>Moderate</td><td>Long<... | <table><tr><td>Driers</td><td>Appearance</td><td>Odor</td><td>Taste</td><td>Flavor</td><td>Texture</td><td>Palability</td><td>Acceptability</td><td>Shelf-life (1–30 days)</td></tr><tr><td>Plastic</td><td>Attractive</td><td>Pleasant</td><td>Fair</td><td>Fair</td><td>Hard</td><td>Good</td><td>Moderate</td><td>Long</td></... | <table><tr><td>Driers</td><td>Appearance</td><td>Odor</td><td>Taste</td><td>Flavor</td><td>Texture</td><td>Palability</td><td>Acceptability</td><td>Shelf-life (1–30 days)</td></tr><tr><td>Glass with black stone</td><td>Very attractive</td><td>Very pleasant</td><td>Very good</td><td>Very good</td><td>Very hard</td><td>V... |
d97c9fa4960ecf7d004a6cb7df773b91033af0a3b9e92542e463c5af5cd11820.png | simple | <table><tr><td>Condition</td><td>EGL</td><td>ESL</td><td>LSL</td><td>ESL (n.a.)</td><td>LSL (n.a.)</td></tr><tr><td>correct</td><td>94.7 (0.9)</td><td>92.0 (1.2)</td><td>82.5 (2.6)</td><td>92.0 (1.6)</td><td>82.1 (3.5)</td></tr><tr><td>semantics</td><td>97.6 (0.8)</td><td>94.2 (1.2)</td><td>94.5 (1.8)</td><td>93.1 (3.4... | <table><tr><td>Condition</td><td>EGL</td><td>ESL</td><td>LSL</td><td>ESL (n.a.)</td><td>LSL (n.a.)</td></tr><tr><td>correct</td><td>94.7 (0.9)</td><td>92.0 (1.2)</td><td>82.5 (2.6)</td><td>92.0 (1.6)</td><td>82.1 (3.5)</td></tr><tr><td>semantics</td><td>97.6 (0.8)</td><td>94.2 (1.2)</td><td>94.5 (1.8)</td><td>93.1 (3.4... | <table><tr><td>Condition</td><td>EGL</td><td>ESL</td><td>LSL</td><td>ESL (n.a.)</td><td>LSL (n.a.)</td></tr><tr><td>syntax</td><td>95.5 (1.9)</td><td>77.3 (4.2)</td><td>80.5 (4.5)</td><td>27.8 (11.6)</td><td>34.3 (10.6)</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.